White Matter Hyperintensities and Cholinergic Deficits as Lewy Body related Degeneration: Imaging-Based Study

Kang, Sungwoo

Department of Medicine

Graduate School

Yonsei University

White Matter Hyperintensities and Cholinergic Deficits as Lewy Body related Degeneration: Imaging-Based Study

Advisor Ye, Byoung Seok

A Dissertation Submitted
to the Department of Medicine
and the Committee on Graduate School
of Yonsei University in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy in Medical Science
Kang, Sungwoo

June 2025

**White Matter Hyperintensities and Cholinergic Deficits as Lewy Body
Related Degeneration: Imaging-Based Study**

**This Certifies that the Dissertation
of Kang, Sungwoo is Approved**

Committee Chair   **Kim, Eosu**

_____

Committee Member   **Ye, Byoung Seok**

_____

Committee Member   **Kim, Se Hoon**

_____

Committee Member   **Lee, Jong-Min**

_____

Committee Member   **Lee, Young-Gun**

_____

**Department of Medicine
Graduate School
Yonsei University
June 2025**

ACKNOWLEDGEMENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF TABLES

ABSTRACT

White matter hyperintensities and cholinergic deficits as Lewy body related degeneration: Imaging-based study

Although basal forebrain (BF) cholinergic degeneration and white matter hyperintensities (WMHs) are important in neurodegeneration in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), their relationships with dopaminergic degeneration and clinical manifestations remain unclear. A total of 407 patients with cognitive impairment meeting the diagnostic criteria for AD, DLB, or both (AD+DLB) were assessed. All participants underwent 3-T MRI, dopamine transporter (DAT) positron emission tomography, neuropsychological tests, and assessments for parkinsonism, cognitive fluctuation, visual hallucination, and rapid eye movement sleep behavior disorder (RBD). General linear and logistic regression models were used to investigate the relationships among BF volume, DAT uptake in the anterior caudate (DAT-AC), WMH volumes in anterior, posterior, periventricular, and deep regions, and clinical manifestations. DAT-AC was positively associated with BF volume and negatively associated with anterior periventricular WMH volume, but not with deep WMHs. Both deep and periventricular WMHs volumes were associated with hypertension and the number of microbleeds and lacunae. Lower BF volume and DAT-AC were independently associated with increased risk of cognitive fluctuation and visual hallucination, whereas lower DAT-AC was additionally associated with increased risk of RBD and greater parkinsonian severity. Both lower BF volume and DAT-AC were independently associated with widespread cognitive impairment, whereas higher anterior periventricular WMH volume was associated with executive dysfunction. BF cholinergic degeneration and anterior periventricular WMHs are closely associated with dopaminergic degeneration. Anterior periventricular WMHs may represent axonal alterations associated with the interplay between Lewy body-related degeneration and vascular pathologies.

Key words: Alzheimer's disease, Lewy body disease, white matter hyperintensities, cholinergic system, dopamine transporter

1. INTRODUCTION

Lewy body disease (LBD), including dementia with Lewy bodies (DLB), is the second most common cause of degenerative dementia, and vascular dementia is the second most common type of dementia after Alzheimer's disease (AD).[1] LBD is characterized not only by the degeneration of the nigrostriatal dopaminergic system but also by the basal forebrain (BF) cholinergic system,[2-4] which is also vulnerable to AD.[5] Previous studies have shown that BF atrophy is linked to cognitive dysfunction in both AD and LBD, with an emphasis on memory domains in AD and with broader cognitive domains in LBD.[6] Moreover, dopaminergic depletion, particularly in the caudate nucleus, is associated with parkinsonism and more severe visuospatial/executive dysfunction in patients with AD,[7] while it is associated with cognitive dysfunction,[8, 9] cognitive fluctuations and hallucinations in DLB.[6] To the best of my knowledge, however, the relationship between dopaminergic depletion, cholinergic degeneration, and clinical symptoms has not been evaluated in cognitively impaired patients, especially considering both AD and LBD.

White matter hyperintensities (WMHs) are core biomarkers of vascular cognitive impairment, particularly subcortical vascular cognitive impairment (SVCI). However, WMHs are frequently observed in patients with AD and/or LBD, and previous studies have shown the role of WMHs in cognitive dysfunction and motor parkinsonism in patients with AD and those with LBD.[10] Although patients with WMHs are usually considered to have vascular pathology, referred to as vascular parkinsonism or vascular cognitive impairment, recent studies have suggested that WMHs may reflect degenerative pathologies rather than vascular pathology.[11-16] In specific, autopsy studies in AD showed that WMHs could be correspondent to axonal degeneration secondary to neurofibrillary tangles, amyloid pathology such as cerebral amyloid angiopathy (CAA), blood-brain barrier disruption, and neuroinflammation.[17] In patients with DLB, WMHs are associated with medial temporal lobe atrophy,[18] cardiovascular autonomic failure,[19] and vascular risk factors.[20] However, some studies have shown that more severe periventricular WMHs (PWMHs) are associated with dopamine transporter loss in patients with Parkinson's disease, independent of vascular risk factors,[21] and associated with the presence of LBD, independent of the presence of AD.[22] Although patients with LBD have frequent concomitant AD pathology, vascular burden, and BF atrophy, the relationships between WMHs, BF cholinergic atrophy, dopaminergic depletion, and clinical symptoms have yet been evaluated simultaneously considering AD and LBD.

In this study, I evaluated the relationship between striatal dopamine transporter (DAT) uptake, BF volume, WMH burden, and clinical symptoms in patients with carefully phenotyped AD, dementia with Lewy bodies (DLB), and mixed dementia (AD+DLB). I hypothesized that DAT depletion and BF atrophy are closely related and simultaneously contribute to the clinical symptoms of dementia. I also hypothesized that WMH burden could be related to vascular risk factors as well as LBD-related brain changes, including DAT depletion or BF atrophy.

2. METHODS

2.1.   Study participants

A total of 1490 patients who were referred to the dementia clinic of Yonsei University Severance Hospital, Seoul, Korea, from July 2015 to September 2023 for the evaluation of cognitive decline were recruited. All patients underwent a neurological examination, neuropsychological tests, 3-T magnetic resonance imaging (MRI), and/or ^{18}F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) DAT positron emission tomography (PET). Clinical features of LBD, including cognitive fluctuation, visual hallucination, and rapid eye movement behavior disorder (RBD) were assessed using semistructured questionnaires answered by caregivers. Motor parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) motor score, which includes subscales for axial symptoms, bradykinesia, rigidity, and tremor.

I included participants who met the following criteria: 1) underwent both MRI and DAT PET; 2) the interval between the MRI and DAT PET was less than 1 year; and 3) participants were aged 50 years or older. The exclusion criteria were as follows: 1) degenerative causes of dementia other than AD and LBD, including frontotemporal dementia, corticobasal degeneration, and progressive supranuclear palsy; 2) drug-induced cognitive impairment or parkinsonism; 3) presence of other causes of cognitive impairment, such as epilepsy, psychiatric disorder, normal pressure hydrocephalus, and structural brain lesions (e.g., tumor or hemorrhage); and 4) MRI artifact or image processing error during quality assurance. Finally, 407 patients were included in this study (Fig. 1).

Fig 1. Flow chart of study participants. Abbreviations: DAT PET, dopamine transporter positron emission tomography; MRI, magnetic resonance imaging; NPH, normal-pressure hydrocephalus; PNFA, progressive nonfluent aphasia; QC, quality control.

A total of 407 subjects were assessed to determine whether they met the diagnostic criteria for AD or DLB based on clinical symptoms and imaging biomarkers as described previously.[23] All AD patients met the criteria for probable AD dementia[24] or AD-related mild cognitive impairment (MCI)[25] based on the National Institute on Aging-Alzheimer's Association workgroup guidelines. All patients with DLB or MCI with Lewy bodies (MCI-LB) were diagnosed based on the 2017 revised criteria for probable DLB[26] and the 2020 research criteria for MCI-LB.[27] If the patients who satisfied the diagnostic criteria of both probable AD and probable DLB were diagnosed with mixed AD/DLB. Therefore, 407 participants were diagnosed as 76 patients with AD, 143 with DLB, and 115 with mixed AD/DLB. The remaining 73 patients had subjective or objective cognitive impairment but did not satisfy the criteria for probable AD or

DLB. I did not exclude these patients because I aimed to simultaneously evaluate the effects of AD, DLB, and vascular diseases on brain changes and cognitive dysfunction. There is a possibility that the cognitive impairment in these 73 patients originated from subthreshold AD or DLB, in addition to vascular disease.

Among 407 participants, 121 (29.7%) underwent 18F-florbetaben (FBB)-PET scans. In the subgroup of 121 subjects who underwent both FBB and DAT PET scans, 20 were diagnosed with amyloid-confirmed AD, 29 with amyloid-confirmed mixed AD/DLB, 6 with amyloid-positive DLB, and 45 with amyloid-negative DLB. The remaining 21 participants did not meet the criteria for probable AD or DLB.

Vascular risk factors, including hypertension, diabetes mellitus, and dyslipidemia, were meticulously investigated, and the number of microbleeds and lacunae were counted individually within the entire brain.

The study protocol was approved by the Institutional Review Board of Yonsei University Medical Center (4-2018-0951). The need for informed consent was waived due to the retrospective nature of the study.

2.2.   Neuropsychological evaluation

All participants completed the standardized Seoul Neuropsychological Screening Battery (SNSB),[28] which comprises tests of attention, language, visuospatial ability, memory, and frontal/executive functions. Standardized z-scores were available for all tests, with scores obtained after age- and education-level matching. The following tests were included in the analyses: the Korean version of the Boston Naming Test for the language domain; the copying item of the Rey−Osterrieth Complex Figure Test (RCFT) for the visuospatial domain; the immediate recall, 20-min delayed recall, and recognition items of the Rey−Osterrieth Complex Figure Test and Seoul Verbal Learning Test (SVLT) for the memory domain; and the digit span backward, semantic (animal), and phonemic Controlled Oral Word Association Test (COWAT) and Stroop Color Test for the executive domain. The scores in each cognitive test were classified as abnormal when they were >1 standard deviation below the normal values.

2.3.   Image acquisition and processing with MRI and PET

The participants were scanned using a Philips 3.0 T MRI scanner (Philips Achieva; Philips Medical Systems, Best, The Netherlands) with a SENSE head coil (SENSE factor = 2). T1-weighted (T1W) MRI scans were obtained using a three-dimensional T1W turbo-field echo sequence with the following parameters: axial acquisition matrix, 224 × 224; reconstructed matrix, 256 × 256 with 170 slices; voxel size, 0.859 × 0.859 × 1 mm3; field of view, 220 mm; echo time, 4.6 ms; repetition time, 9.8 ms; and flip angle, 8°.

FP-CIT and FBB PET scans were obtained using a Discovery 600 system (General Electric Healthcare, Milwaukee, WI, USA). A dose of 185 MBq (5 mCi) FP-CIT or 300 MBq (8 mCi) FBB was injected intravenously during the procedure. Ninety minutes after injection, images

were acquired over a 20-min session. The images were reconstructed using the ordered subset expectation-maximization algorithm with four iterations and 32 subsets. A Gaussian filter with a 4-mm full width at half maximum (FWHM) kernel was applied to the reconstructed PET images, yielding a 256 × 256 matrix with 0.98-mm pixels and 0.98-mm slice thickness.

An overview of the image processing workflow for WMH, BF, and striatal DAT quantification is illustrated in Fig 2. Detailed acquisition parameters and processing steps are described below.

Quantification of WMH volumes	Quantification of BF volumes	Quantification of striatal DAT uptake
MRI acquisition (T1-weighted, FLAIR)	MRI acquisition (T1-weighted)	MRI and FP-CIT PET image acquisition
Intensity non-uniformity correction & excluding nonbrain tissue	Intensity non-uniformity correction & excluding nonbrain tissue	Co-registration of PET and MRI images
Co-registration of FLAIR to T1-weighted	Tissue segmentation (Gray matter, White matter, CSF)	Striatal segmentation based on MRI (FSL FIRST algorithm)
WMH segmentation using U-Net convolutional neural network	Non-linear registration to MRI template (MNI space)	Calculation of standardized uptake value ratio in striatum (occipital white matter as reference region)
Classification of WMHs into 4 regions (anterior periventricular, posterior periventricular, anterior deep, posterior deep)	Basal forebrain ROI definition (Ch4, SPM anatomy toolbox)	Subdivision of striatal regions (anterior caudate, posterior caudate, anterior putamen, posterior putamen)
	Summation of gray matter voxel within ROI to extract basal forebrain volume	

Fig 2. Flow chart of imaging processing. Abbreviations: BF, basal forebrain; CSF, cerebrospinal fluid; DAT, dopamine transporter; MRI, magnetic resonance imaging; PET, positron emission tomography; ROI, region of interest; WMH, white matter hyperintensities.

2.4.   Quantification of WMH volumes

T1W and FLAIR (fluid-attenuated inversion recovery) scans were processed using the MINC toolkit (https://bic-mni.github.io). I corrected the images for intensity nonuniformities and excluded non-brain tissue followed by co-registration using a rigid body transformation. T1W images were linearly registered to the Alzheimer's Disease Neuroimaging Initiative (ADNI)-Montreal Neurological Institute (MNI) atlas, a specific T1W template for the older individuals.[29] WMH segmentation was performed using a U-Net convolutional neural network, optimized to highlighting partial-volume WMHs, thereby enhancing segmentation accuracy.[30] I classified periventricular WMHs (PWMHs) as those within a 10-mm sphere along ventricular cerebrospinal fluid edges and deep WMHs (DWMHs) in other white matter areas. These were further divided, based on their anterior/posterior location, using a split point of y=-18 in the MNI space, into four categories: anterior PWMH (PWMH-A), posterior PWMH (PWMH-P), anterior DWMH

5

(DWMH-A), and posterior DWMH (DWMH-P). For voxel-based analysis, WMH voxels were non-linearly transformed into the ADNI-MNI atlas via each participant's T1W images using the Advanced Normalization Tools Symmetric Normalization (ANTs SyN) registration algorithm and then resampled using nearest-neighbors before being blurred with an 8-mm FWHM Gaussian kernel.

2.5. Quantification of BF volume

T1W images were processed using the FMRIB Software Library (FSL, http://www.fmrib.ox.ac.uk/fsl) and the optimized voxel-based morphometry protocol.[31] To minimize bias in tissue segmentation due to white matter lesions, these hypo-intense areas in T1W images were filled with intensities from surrounding normal-appearing brain tissue on the inhomogeneity-corrected image as described in a previous study.[32] The images were then brain-extracted and segmented into different tissue types (gray matter, white matter, and cerebrospinal fluid), based on a hidden Markov random field model and an associated Expectation-Maximization algorithm, and aligned to the MNI standard space. A study-specific symmetric template was created, and gray matter images were non-linearly registered to this template and modulated.[31] The modulated gray matter images were then smoothed with 4-mm FWHM Gaussian kernels. The BF region-of-interest (ROI) was identified using the Statistical Parametric Mapping Anatomy Toolbox. BF volumes were derived by summing the modulated gray matter voxel values within Ch4 masks, created using a combination of post-mortem MRI and histology from ten autopsied brains.[33]

2.6. Quantification of striatal DAT uptake

ROIs in the striatum were segmented using the FSL FIRST algorithm based on parameterized deformable surface meshes.[34] FP-CIT PET scans were co-registered to individual T1W MRI scans, and standardized uptake value ratio (SUVR) maps of the FP-CIT PET images were generated using occipital white matter as the reference region. The FP-CIT PET images were then smoothed using a 6-mm FWHM Gaussian kernel. Following the anteroposterior axis, I designated the front two-fifths of the putamen and caudate as the anterior segments and the rear two-fifths as the posterior segments. The median SUVRs of the FP-CIT PET scans from these segmented ROIs were calculated including the anterior caudate (DAT-AC), posterior caudate (DAT-PC), anterior putamen (DAT-AP), and posterior putamen (DAT-PP).

2.7. Quality assurance for image processing

All MRI and PET images and pre-processing outcomes from the automated pipelines were visually inspected for quality assurance by three researchers (SWK, SJ, and BSY) who were blinded to the participants' information. Eight participants were excluded from the initial dataset due to image processing errors and MRI artifacts, resulting in the final inclusion of 407 participants in this study.

2.8. Statistical analysis

Statistical analyses of demographic and clinical data were performed using the R statistical software (version 4.2.1). GLMs were used to evaluate the association among BF volume, WMHs, and striatal DAT uptake after controlling for age, sex, education, vascular factors (hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, and number of lacunae), and intracranial volume. The same analyses for voxel-wise associations between DAT uptakes and WMHs were performed using the SurfStat toolbox (http://www.math.mcgill.ca/keith/surfstat).

As DAT-AC had the highest Pearson correlation coefficient with the relationship between BF volume and PWMH-A (Fig. 3), BF volume, DAT-AC, and PWMH-A were used as main predictors in GLMs or logistic models to determine their effects on neuropsychological test z-scores, parkinsonian motor severity, and risk of cognitive fluctuation, visual hallucination, and RBD after controlling for the same covariates.

Fig 3. Pearson correlation analysis between BFV, WMHs and striatal DAT uptake. Values representing correlation coefficient and significant correlations (P < 0.05) are displayed without an 'x' mark; non-significant values retain an 'x' mark. Abbreviations: AC, anterior caudate; AP, anterior putamen; BFV, basal forebrain volume; DAT, dopamine transporter; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DMWH, PMWH-A, anterior periventricular WMH; PWMH-P, posterior PWMH.

Explorative analyses of the three-way or two-way interactions of BF volume, DAT-AC, and PWMH-A on clinical outcomes were conducted by controlling for the same covariates.

The independent effects of AD and DLB on the BF volume, DAT-AC, and PWMH-A were investigated using GLMs in the whole participants and in the subgroup who underwent both FBB and DAT PET after controlling for the same covariates.

For above statistical analyses, sensitivity analyses were conducted by excluding 73 patients who did not satisfy the criteria for probable AD or DLB from the whole participants. The sensitivity analyses were then performed separately for the non-AD/non-DLB (N = 73), AD (N = 76), DLB (N = 143), mixed (AD/DLB, N = 115), and combined DLB + AD/DLB (N = 258) subgroups.

2.9.   Data availability

To replicate the procedures and results, any qualified investigator can request anonymized data after obtaining ethics clearance and approval from all authors.

3. RESULTS

3.1.   Demographic and clinical characteristics of the participants

The demographic and clinical characteristics of the study participants are shown in Table 1.

Table 1. Demographics of study participants

Number	407
Age, y	76.9 ± 7.2
Female, n (%)	233 (57.2%)
Education	10.3 ± 4.7
Dementia stage, n (%)	
SCD	78 (19.2%)
MCI	167 (41.0%)
Dementia	162 (39.8%)
K-MMSE	23.4 ± 4.1
UPDRS part III motor total score	25.5 ± 14.0
Axial symptoms	5.7 ± 3.9
Bradykinesia	14.1 ± 7.9
Rigidity	4.8 ± 3.4
Tremor	0.4 ± 0.7
DLB clinical features, n (%)	
Cognitive fluctuation	197 (48.4%)

Visual hallucination	61 (15.0%)
RBD	134 (32.9%)
Vascular risk factors, n (%)	
Hypertension	270 (66.3%)
Diabetes mellitus	123 (30.2%)
Dyslipidemia	224 (55.0%)
Subjects with microbleeds	191 (47.0%)
Subjects with lacunae	116 (28.6%)
Diagnosis, n (%)	
Clinical AD	191 (46.9%)
Amyloid confirmed AD	49 (12.0%)
DLB	258 (63.4%)
Mixed disease	115 (28.3%)
Subjects who underwent FBB PET, n (%)	121 (29.7%)

Data are expressed as means (SD) or numbers (%). Abbreviations: AD, Alzheimer's disease; DLB; dementia with Lewy bodies; FBB PET, ^{18}F-florbetaben positron emission tomography; K-MMSE, Korean version of the Mini-Mental State Examination; MCI, mild cognitive impairment; RBD, rapid eye movement sleep behavior disorder; SCD, subjective cognitive decline; UPDRS, Unified Parkinson's Disease Rating Scale.

The mean participant age was 76.9±7.2 years, and the mean years of education was 10.3±4.7 years. Of the 407 participants, 270 (66.3%) had hypertension, 123 (30.2%) had diabetes mellitus, and 224 (55.0%) had dyslipidemia. Seventy-eight participants (19.2%) had subjective cognitive impairment, 167 (41.0%) had mild cognitive impairment, and 162 (39.8%) had dementia. The mean K-MMSE score was 23.4±4.1. The mean UPDRS motor score at the time of DAT PET was 25.5±14.0. One hundred and ninety-seven participants (48.4%) had cognitive fluctuation, 61 (15.0%) had visual hallucination, and 134 (32.9%) had RBD. On brain MRI, 191 participants (47%) had microbleeds and 116 (28.6%) had lacunae. One hundred and ninety-one participants (46.9%) were clinically diagnosed with AD, 258 (63.4%) were diagnosed with DLB, and 115 (28.3%) had mixed AD/DLB. The demographic and clinical characteristics of the subgroup who underwent both FBB and DAT PET (N = 121, 29.7%) are presented in Table 2.

Table 2. Demographic of subgroup who performed both FBB and DAT PET

Number	121
Age	75.7 ± 7.2
Female, N (%)	67 (55.4%)
Education	10.0 ± 4.6
Dementia stage, N (%)	
SCD	19 (15.7%)
MCI	45 (37.2%)
Dementia	57 (47.1%)
K-MMSE	22.9 ± 4.0
UPDRS part III motor score	19.0 ± 13.5
Axial symptoms	4.0 ± 3.6
Bradykinesia	10.6 ± 7.9
Rigidity	3.6 ± 3.3
Tremor	0.4 ± 0.6
DLB clinical features, N (%)	
Cognitive fluctuation	65 (53.7%)
Visual hallucination	20 (16.5%)
RBD	42 (34.7%)
Vascular risk factors, N (%)	
Hypertension	62 (51.2%)
Diabetes mellitus	28 (23.1%)
Dyslipidemia	57 (47.1%)
Subjects with microbleeds	44 (36.7%)
Subjects with lacunes	32 (26.7%)
Diagnosis, N (%)	
Amyloid confirmed AD	49 (40.5%)
DLB	80 (66.1%)
Mixed disease	29 (24.0%)

Amyloid positive, N (%)	56 (46.3%)

Data are expressed as means (SD) or numbers (%). Abbreviations: AD, Alzheimer's disease; DAT, dopamine transporter; DLB, dementia with Lewy bodies; FBB, ^{18}F-Florbetaben; K-MMSE, Korean version of mini-mental state examination; MCI, mild cognitive impairment; PET, positron emission tomography; RBD, rapid eye movement sleep behavior disorder; SCD, subjective cognitive decline; UPDRS, unified Parkinson's disease rating scale. The demographic and clinical characteristics of the subgroups (non-AD/non-DLB, AD, DLB, and mixed AD/DLB) are shown in Table 3.

Table 3. Demographics of the Non-AD/Non-DLB, AD, DLB, and AD/DLB Subgroups

	Non-AD/Non-DLB (N=73)	AD (N=76)	DLB (N=143)	AD/DLB (N=115)	P
Age, y	74.9 ± 6.7	77.0 ± 7.5	76.2 ± 7.1	78.9 ± 7.1[†※]	**0.001**
Female, n (%)	51 (69.9%)[※]	49 (64.5%)[※]	69 (48.3%)[†‡]	64 (55.7%)	**0.011**
Education	10.7 ± 4.6	10.8 ± 4.7	9.7 ± 4.6	10.4 ± 4.6	0.260
Dementia stage, n (%)					**< 0.001**
SCD	39 (53.4%)	14 (18.4%)	19 (13.3%)	6 (5.2%)	
MCI	28 (38.4%)	40 (52.6%)	61 (42.7%)	38 (33%)	
Dementia	6 (8.2%)[‡※]	22 (28.9%)[†]	63 (44.1%)[†]	71 (61.7%)[†‡※]	
K-MMSE	26.2 ± 3.0[‡※]	23.9 ± 3.3[†]	22.9 ± 4.1[†]	21.9 ± 4.4[†‡※]	**< 0.001**
UPDRS part III motor total score	20.9 ± 13.6	23.8 ± 11.0	25.9 ± 15.1	29.1 ± 13.7[†]	**< 0.001**
Axial symptoms	4.4 ± 3.6[※]	5.3 ± 3.4	5.9 ± 3.8[†]	6.6 ± 4.3[†]	**0.001**
Bradykinesia	11.8 ± 7.7	13.4 ± 6.7	14.2 ± 8.6	15.8 ± 7.6[†]	**0.006**
Rigidity	4.2 ± 3.5	4.5 ± 2.5	4.9 ± 3.8	5.4 ± 3.2	0.078
Tremor	0.4 ± 0.8	0.3 ± 0.5	0.5 ± 0.6	0.5 ± 0.7	0.344
DLB clinical features, n (%)					
Cognitive fluctuation	0 (0%)[※]	0 (0%)[※]	101 (70.6%)[†‡]	96 (83.5%)[†‡※]	**< 0.001**
Visual hallucination	0 (0%)[※]	0 (0%)[※]	39 (27.3%)[†‡]	22 (19.1%)[†‡]	**< 0.001**
RBD	1 (1.4%)[※]	3 (3.9%)[※]	83 (58%)[†‡]	47 (40.9%)[†‡※]	**< 0.001**
Vascular risk factors, n (%)					
Hypertension	47 (64.4%)	47 (61.8%)	95 (66.4%)	81 (70.4%)	0.642
Diabetes mellitus	23 (31.5%)	21 (27.6%)	44 (30.8%)	35 (30.4%)	0.956

Dyslipidemia	46 (63%)	36 (47.4%)	86 (60.1%)	56 (48.7%)	0.070
Subjects with microbleeds	33 (45.2%)	38 (50%)	63 (44.4%)	57 (49.6%)	0.785
Subjects with lacunae	20 (27.4%)	18 (23.7%)	47 (33.1%)	31 (27%)	0.473

Data are expressed as means ± SD or numbers (%). Group comparisons were performed using the chi-square test or Fisher's exact test, and analysis of variance as appropriates. [†]Significantly different from Non-AD/DLB. [‡]Significantly different from AD. [※]Significantly different from DLB. Abbreviations: AD, Alzheimer's disease; DLB; dementia with Lewy bodies; K-MMSE, Korean version of the Mini-Mental State Examination; MCI, mild cognitive impairment; RBD, rapid eye movement sleep behavior disorder; SCD, subjective cognitive decline; UPDRS, Unified Parkinson's Disease Rating Scale.

3.2.   Effect of BF volume and regional WMHs on striatal DAT uptake

Univariable regression analysis showed that decreased BF was associated with decreased DAT uptake in all regions (Table 4). Among striatal regions, DAT-AC had the highest standardized β coefficient for predicting BF volume. Increased PWMH-A was associated with decreased DAT-AC.

Table 4. Effect of BFV and WMHs on striatal DAT uptake

	BFV		PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	P	B	P	B	P	B	P	B	P
DAT										
AP	0.21	**< 0.001**	-0.09	0.109	-0.03	0.558	-0.07	0.175	-0.01	0.907
PP	0.16	**0.003**	-0.08	0.151	-0.004	0.939	-0.05	0.322	0.01	0.889
AC	0.27	**< 0.001**	-0.19	**0.001**	-0.09	0.101	-0.10	0.034	-0.04	0.365
PC	0.25	**< 0.001**	-0.14	0.012	-0.02	0.670	-0.06	0.215	0.004	0.933

Univariable general linear models were used to investigate effects of BFV and WMHs on striatal DAT uptake after controlling for age, sex, education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of regressions analyses for 20 tests. Abbreviations: AC, anterior caudate; AP, anterior putamen; BFV, basal forebrain volume; DAT, dopamine transporter uptake; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PC, posterior caudate; PP, posterior putamen; PWMH-A, anterior periventricular WMH; PWMH-P, posterior PWMH.

Univariable or multivariable voxel-wise GLMs showed that decreased BF volume was associated with decreased striatal DAT uptake, with emphasis on the AC, and increased PWMH-A was associated with decreased DAT uptake in the anterior striatum, with emphasis on the caudate (Fig. 4 A and B).

Fig 4. Voxel-wise analyses for the associations between DAT uptakes and WMHs. Univariable analyses for voxel-wise DAT uptake using BF volume and PWMH-A as a predictor (A). Multivariable analysis for voxel-wise DAT uptake using BF volume and PWMH-A as predictors (B). Univariable analyses for voxel-wise WMHs using BF volume and DAT-AC as a predictor (C). Multivariable analyses for voxel-wise WMHs using BF volume and DAT-AC as predictors (D). All analyses were performed after controlling for age, sex, education, intracranial volume, hypertension, diabetes, dyslipidemia, microbleeds, and lacunes. Negative correlations between WMH and DAT were tested. Effect sizes (r score) were indicated by color intensities within statistically significant regions identified by multiple comparisons correction (false discovery rate [FDR] corrected, $P < 0.05$). Abbreviations: AC, anterior caudate; BF, basal forebrain; DAT, dopamine transporter uptake; WMH, white matter hyperintensities; PWMH-A, anterior periventricular WMH.

The effects of other WMHs on striatal DAT uptake are shown in **Fig. 5**.

Fig 5. Voxel-wise analyses for the associations between DAT uptakes and WMHs. Univariable analyses for voxel-wise DAT uptake using one of the four regional WMHs as a predictor (A). Multivariable analysis for DAT uptake using one of the four regional WMHs and BF volume as predictors (B). Univariable analyses for voxel-wise WMHs using one of the four regional DAT uptake as a predictor (C). Multivariable analyses for voxel-wise WMHs using one of the four regional DAT uptake and BF volume as predictors (D). All analyses were performed after controlling for age, sex, education, intracranial volume, hypertension, diabetes, dyslipidemia, microbleeds, and lacunes. Negative correlations between WMH and DAT were tested. Effect sizes (r score) were indicated by color intensities within statistically significant regions identified by multiple comparisons correction (false discovery rate [FDR] corrected, $P < 0.05$). Abbreviations: AC, anterior caudate; AP, anterior putamen; BF, basal forebrain; DAT, dopamine transporter uptake; WMH, white matter hyperintensities; DWMH-A, anterior deep WMH; DWMH-P, posterior DWMH; PWMH-A, anterior periventricular WMH; PWMH-P, posterior PWMH.

3.3. Effect of BF volume, striatal DAT uptake, and vascular factors on regional WMHs

Univariable regression analysis showed that decreased BF volume, decreased caudate DAT, presence of hypertension, increased number of microbleeds, and increased number of lacunae were associated with increased PWMH-A (Table 5). The BF volume and striatal DAT uptake were not associated with the PWMH-P or DWMH. The presence of hypertension, increased number of microbleeds, and increased number of lacunae were also associated with increased PWMH-P and DWMHs.

Table 5. Effect of BF volume, striatal DAT uptake, and vascular factors on WMHs

Predictors	PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	*P*	B	*P*	B	*P*	B	*P*
Univariable analysis								
BF volume	-0.12	**0.007**	-0.06	0.233	-0.04	0.417	0.03	0.632
DAT								
AP	-0.07	0.109	-0.03	0.558	-0.07	0.175	-0.01	0.907
PP	-0.06	0.151	-0.004	0.939	-0.05	0.322	0.01	0.889
AC	-0.16	**0.001**	-0.08	0.101	-0.11	0.034	-0.05	0.365
PC	-0.12	**0.012**	-0.02	0.670	-0.06	0.215	0.004	0.933
Vascular factors								
Hypertension	0.12	**0.009**	0.12	**0.013**	0.12	**0.017**	0.10	0.047
Diabetes mellitus	0.09	0.050	0.06	0.178	0.005	0.920	0.02	0.709
Dyslipidemia	0.07	0.150	0.05	0.289	0.04	0.448	0.03	0.487
Microbleeds	0.31	**< 0.001**	0.33	**< 0.001**	0.32	**< 0.001**	0.24	**< 0.001**
Lacunae	0.39	**< 0.001**	0.35	**< 0.001**	0.30	**< 0.001**	0.30	**< 0.001**
Multivariable analysis								
BF volume	-0.09	0.065	-0.04	0.432	-0.01	0.800	0.04	0.450
DAT-AC	-0.13	**0.006**	-0.07	0.188	-0.10	0.054	-0.06	0.283
Hypertension	0.10	**0.021**	0.10	**0.026**	0.11	**0.026**	0.08	0.106
Diabetes mellitus	0.03	0.439	0.02	0.711	-0.04	0.391	-0.01	0.779
Dyslipidemia	0.03	0.468	0.02	0.669	0.03	0.586	0.02	0.620
Microbleeds	0.27	**< 0.001**	0.29	**< 0.001**	0.28	**< 0.001**	0.20	**< 0.001**
Lacunae	0.33	**< 0.001**	0.29	**< 0.001**	0.24	**< 0.001**	0.26	**< 0.001**

General linear models were used to investigate the effects of BF volume, striatal DAT, and vascular factors on WMHs, after controlling for age, sex, level of education, and intracranial volume. In the univariable analysis, significant *P*-values are shown in boldface after false discovery rate correction of 40 regression analyses for multiple comparisons across the 10

predictors and four outcomes. In the multivariable analysis, significant *P*-values are shown in boldface after false discovery rate correction of the four regression analyses for multiple comparisons across the four outcomes. Abbreviations: B, standardized β coefficient; AC, anterior caudate; AP, anterior putamen; BF, basal forebrain; DAT, dopamine transporter; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PC, posterior caudate; PP, posterior putamen; PWMH-A, anterior periventricular white matter hyperintensities; PWMH-P, posterior periventricular white matter hyperintensities.

When BF volume, DAT-AC, and vascular factors were simultaneously entered into GLMs for WMHs, the presence of hypertension, increased number of microbleeds, and increased number of lacunae were associated with increased PWMHs and DWMHs, independent of BF volume and DAT-AC, except for the presence of hypertension for DWMH-P. Decreased DAT-AC was associated with increased PWMH-A independent of BF volume and vascular factors, whereas decreased BF volume was tended to be associated with PWMH-A but not with other WMHs.

The univariable and multivariable voxel-wise GLMs showed that both decreased BF volume and DAT-AC were associated with higher PWMHs, mainly in the anterior direction (Fig. 3 C and D). The effects of other striatal DAT uptakes on WMHs are shown in Fig. 4.

3.4. Effect of BF volume, DAT-AC, and PWMH-A on LBD features

Univariable regression analysis demonstrated that decreased BF volume was associated with an increased risk of cognitive fluctuation and visual hallucination, and decreased DAT-AC was further associated with an increased risk of RBD, whereas PWMH-A was not associated with LBD features (Table 6). Multivariable regression analysis showed that decreased BF volume was independently associated with an increased risk of cognitive fluctuation and visual hallucinations, and decreased DAT-AC was independently associated with an increased risk of cognitive fluctuation, visual hallucination, and RBD.

Table 6. Effect of BF volume, DAT-AC, and PWMH-A on DLB features

	BF volume		DAT-AC		PWMH-A	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Univariable analysis						
Cognitive fluctuation	0.97 (0.96~0.98)	**< 0.001**	0.66 (0.55~0.79)	**< 0.001**	1.00 (1.00~1.00)	0.129
Visual hallucination	0.97 (0.96~0.98)	**< 0.001**	0.55 (0.43~0.70)	**< 0.001**	1.00 (1.00~1.00)	0.995
RBD	0.99 (0.98~1.00)	0.151	0.74 (0.62~0.88)	**0.001**	1.00 (1.00~1.00)	0.880
Multivariable analysis						
Cognitive fluctuation	0.97 (0.96~0.98)	**< 0.001**	0.74 (0.60~0.89)	**0.002**	1.00 (1.00~1.00)	0.711

Visual hallucination	0.98 (0.96~0.99)	**0.008**	0.60 (0.46~0.78)	**< 0.001**	1.00 (1.00~1.00)	0.334
RBD	1.00 (0.99~1.01)	0.559	0.74 (0.61~0.89)	**0.002**	1.00 (1.00~1.00)	0.444

Data are the results of logistic regression models of DLB clinical features (cognitive fluctuation, visual hallucination, and RBD) using BF volume, DAT-AC, and PWMH-A as predictors after controlling for age, sex, level of education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of regression analyses for 9 univariable analyses and 3 multivariable analyses. Abbreviations: BF, basal forebrain; CI, confidence interval; DAT-AC, dopamine transporter uptake in the anterior caudate; DLB, dementia with Lewy bodies; OR, odds ratio; PWMH-A, anterior periventricular white matter hyperintensities; RBD, rapid eye movement sleep behavior disorder.

Table 7 shows the effects of BF volume, DAT-AC, and PWMH-A on UPDRS motor scores, including the subscores of axial symptoms, bradykinesia, rigidity, and tremor. Univariable regression analysis showed that decreased BF volume was associated with higher UPDRS motor scores as well as subscores of bradykinesia; and decreased DAT-AC was associated with higher UPDRS motor scores and all subscores. Multivariable regression analysis showed that decreased DAT-AC was associated with UPDRS motor scores and bradykinesia and rigidity subscores, independent of BF volume and PWMH-A, whereas BF volume and PWMH-A were not associated with the total UPDRS score or its subscores.

Table 7. Effect of BF volume, DAT-AC, and PWMH-A on parkinsonism

	BF volume		DAT-AC		PWMH-A	
	B	*P*	B	*P*	B	*P*
Univariable analysis						
Total UPDRS motor score	-0.16	**0.005**	-0.25	**< 0.001**	0.09	0.135
Axial	-0.11	0.046	-0.14	**0.015**	0.14	0.025
Bradykinesia	-0.16	**0.005**	-0.25	**< 0.001**	0.08	0.214
Rigidity	-0.12	0.042	-0.23	**< 0.001**	0.06	0.362
Tremor	-0.09	0.127	-0.12	**0.031**	0.05	0.463
Multivariable analysis						
Total UPDRS motor score	-0.10	0.091	-0.21	**< 0.001**	0.04	0.489
Axial	-0.07	0.199	-0.09	0.125	0.11	0.069
Bradykinesia	-0.10	0.087	-0.21	**< 0.001**	0.03	0.646
Rigidity	-0.06	0.345	-0.22	**< 0.001**	0.01	0.873

Tremor	-0.07	0.266	-0.08	0.208	0.00	0.986

General linear models were used to investigate the effects of BF volume, DAT-AC, and PWMH-A on parkinsonism after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction for multiple comparisons of regression analyses for 15 univariable analyses and 4 multivariable analyses for 4 subscores of the UPDRS motor score. Abbreviations: B, standardized β coefficient; BF, basal forebrain; DAT-AC, dopamine transporter uptake in the anterior caudate; PWMH-A, anterior periventricular white matter hyperintensities; UPDRS, Unified Parkinson's Disease Rating Scale.

3.5.   Effect of BF volume, DAT-AC, and PWMH-A on cognition

Univariable regression analysis demonstrated that decreased BF volume and DAT-AC and increased PWMH-A were associated with widespread cognitive dysfunction (Table 8).

Table 8. Univariable analysis of the effect of BF volume, DAT-AC, and PWMH-A on cognition

	BF volume		DAT-AC		PWMH-A	
	B	P	B	P	B	P
Digit span Backward	0.01	0.882	0.10	0.070	-0.18	**0.004**
K BNT	0.28	**< 0.001**	0.23	**< 0.001**	-0.18	**0.004**
RCFT copy	0.23	**< 0.001**	0.25	**< 0.001**	-0.14	**0.023**
SVLT immediate recall	0.32	**< 0.001**	0.29	**< 0.001**	-0.17	**0.005**
SVLT delayed recall	0.32	**< 0.001**	0.23	**< 0.001**	-0.19	**0.002**
SVLT recognition	0.25	**< 0.001**	0.16	**0.003**	-0.11	0.071
RCFT immediate recall	0.32	**< 0.001**	0.24	**< 0.001**	-0.12	**0.038**
RCFT delayed recall	0.30	**< 0.001**	0.25	**< 0.001**	-0.13	**0.030**
RCFT recognition	0.29	**< 0.001**	0.22	**< 0.001**	-0.16	**0.009**
COWAT animal	0.34	**< 0.001**	0.26	**< 0.001**	-0.24	**< 0.001**
COWAT phonemic	0.18	**0.001**	0.17	**0.002**	-0.13	**0.032**
Stroop color reading	0.32	**< 0.001**	0.25	**< 0.001**	-0.24	**< 0.001**

Univariable general linear models were used to investigate effects of BF volume, DAT-AC, and PWMH-A hyperintensities on cognition after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. Abbreviations: BF, basal forebrain; COWAT, controlled oral word association test; DAT-AC,

dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston naming test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey–Osterrieth complex figure Test; SVLT, Seoul verbal learning test.

Multivariable regression analysis showed that the effects of decreased BF volume and DAT-AC on cognitive dysfunction remained significant except for SVLT recognition and COWAT phonemic in terms of DAT-AC (Table 9). In contrast, the effects of increased PWMH-A on cognitive dysfunction were significant only in the digit span backward, COWAT animal, and Stroop color reading tests.

Table 9. Multivariable analysis of the effect of BF volume, DAT-AC, and PWMH-A on cognition

	BF volume		DAT-AC		PWMH-A	
	B	P	B	P	B	P
Digit span backward	-0.04	0.523	0.09	0.117	-0.17	**0.008**
K-BNT	0.23	**< 0.001**	0.14	**0.016**	-0.12	0.047
RCFT copy	0.16	**0.003**	0.19	**0.001**	-0.08	0.193
SVLT immediate recall	0.25	**< 0.001**	0.20	**< 0.001**	-0.10	0.101
SVLT delayed recall	0.27	**< 0.001**	0.14	**0.014**	-0.13	0.028
SVLT recognition	0.22	**< 0.001**	0.09	0.122	-0.06	0.306
RCFT immediate recall	0.27	**< 0.001**	0.16	**0.005**	-0.05	0.353
RCFT delayed recall	0.24	**< 0.001**	0.17	**0.002**	-0.06	0.302
RCFT recognition	0.24	**< 0.001**	0.13	**0.023**	-0.10	0.094
COWAT animal	0.28	**< 0.001**	0.15	**0.009**	-0.17	**0.004**
COWAT phonemic	0.14	**0.018**	0.12	0.043	-0.10	0.122
Stroop color reading	0.26	**< 0.001**	0.14	**0.011**	-0.17	**0.003**

Multivariable general linear models were used to investigate the effects of BF volume, DAT-AC, and PWMH-A on cognition, after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction for multiple comparisons of the regression analyses of 12 tests. Abbreviations: B, standardized β coefficient; BF, basal forebrain; COWAT, Controlled Oral Word Association Test; DAT-AC, dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston Naming Test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey–Osterrieth Complex Figure Test; SVLT, Seoul Verbal Learning Test.

Explorative analyses of two-way or three-way interactions on all cognitive test scores revealed significant BF volume×DAT-AC interactions for the K-BNT and RCFT copy and BF volume×PWMH-A interactions for the digit span backward (Table 10).

Table 10. Interaction effect of BFV, PWMH-A and DAT-AC on digit span backward, K-BNT, and RCFT copy

	BFV		DAT-AC		PWMH-A		BFV ×DAT-AC		BFV ×PWMH-A		DAT-AC ×PWMH-A	
	B	P	B	P	B	P	B	P	B	P	B	P
Digit span Backward[*]	-0.14	0.070	0.11	0.077	-0.90	**0.011**		N.S	0.73	**0.034**		N.S.
K-BNT[*]	0.73	**0.004**	0.73	**0.014**	-0.12	0.045	-0.94	**0.042**		N.S.		N.S.
RCFT copy[*]	0.65	**0.008**	0.75	**0.008**	-0.08	0.187	-0.90	**0.043**		N.S.		N.S.

Multivariable general linear models were used to investigate effects of BFV, DAT-AC and PWMH-A on cognition after controlling for age, sex, education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. [*]As the interaction terms of BFV×PWMH for digit span backward and BFV×DAT-AC for K-BNT and RCFT copy tests were significant, interaction terms were simultaneously entered as predictors. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of regressions analyses for K-BNT and RCFT copy tests. Abbreviations: BFV, basal forebrain volume; DAT-AC, dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston naming test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey−Osterrieth complex figure Test.

Fig. 6 demonstrated detrimental synergistic interactions of BF volume×DAT-AC or BF volume×PWMH-A on deficits in those tests.

**Fig 6.** Interaction effect of BFV, PWMH-A and DAT-AC on digit span backward, K-BNT, and RCFT copy. Abbreviations: BFV, basal forebrain volume; DAT-AC, dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston naming test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey−Osterrieth complex figure Test.

3.6. Independent effect of AD and DLB on BF volume, DAT-AC, and PWMH-A

The presence of AD was independently associated with decreased BF volume, whereas the presence of DLB was independently associated with decreased BF volume and DAT-AC in all participants and the subgroup 1 that underwent both FBB and DAT PET scans (**Table 11**). When the analysis was limited to the subgroup 1, the presence of DLB was associated with increased PWMH-A, independent of the presence of AD.

Table 11. Independent effect of AD and DLB on BFV, DAT-AC and PWMH-A

	AD				DLB			
	Beta	SE	B	P	Beta	SE	B	P
Whole subjects, N=407								
BFV	-7.69	2.11	-0.16	**< 0.001**	-10.68	2.18	-0.21	**< 0.001**
DAT-AC	0.11	0.12	0.04	0.387	-0.59	0.13	-0.20	**< 0.001**
PWMH-A	116.69	556.58	0.01	0.834	744.40	573.28	0.05	0.195
Subgroup 1, N=121								
BFV	-7.81	3.61	-0.18	**0.033**	-10.45	3.78	-0.23	**0.007**
DAT-AC	0.08	0.24	0.03	0.736	-0.78	0.25	-0.26	**0.002**
PWMH-A	-44.39	853.48	-0.003	0.959	2018.99	893.60	0.15	**0.026**
Subgroup 2, N=334								
BFV	-6.85	2.64	-0.15	**0.010**	-10.09	3.05	-0.18	**0.001**
DAT-AC	0.02	0.16	0.01	0.895	-0.73	0.18	-0.22	**< 0.001**
PWMH-A	-41.81	713.40	-0.003	0.953	749.30	823.20	0.05	0.363
Subgroup 3, N=100								
BFV	-11.59	4.70	-0.26	**0.016**	-15.47	5.83	-0.28	**0.009**
DAT-AC	-0.11	0.31	-0.04	0.723	-1.09	0.38	-0.31	**0.006**
PWMH-A	-454.50	1132.00	-0.04	0.689	1561.00	1406.00	0.10	0.270

Multivariable general linear models were used to investigate effects of presence of AD and DLB on BFV, DAT-AC, and PWMH-A after controlling for age, sex, education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. The subjects in subgroup 1 additionally performed FBB-PET. Subgroup 2 consisted of subjects excluding 73 subjects who did not meet the criteria of probable AD or DLB from whole participants. Subgroup 3 consisted of subjects excluding 21 subjects who did not meet the criteria of probable AD or DLB from subgroup 1. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of 3 regression analyses for BFV, DAT-AC and PWMH-A. Abbreviations: AD, Alzheimer's disease; B, standardized beta coefficient; BFV, basal forebrain volume; DAT-AC;

dopamine transporter uptake in the anterior caudate; DLB, dementia with Lewy bodies; PWMH-A;
anterior periventricular white matter hyperintensities; SE, standard error.

3.7. Sensitivity analyses

Even after excluding 73 patients who did not satisfy the criteria for probable AD or DLB, all the
results on sensitivity analyses are very similar to main results (**Table 12-17**).

Table 12. Effect of BFV, striatal DAT uptake, and vascular factors on WMHs after excluding 73
patients who did not satisfy the criteria for probable AD and DLB

Predictors	PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	*P*	B	*P*	B	*P*	B	*P*
Univariable analysis								
BFV	-0.11	0.037	-0.06	0.258	-0.01	0.818	0.03	0.596
DAT								
AP	-0.09	0.105	-0.05	0.399	-0.07	0.225	-0.03	0.551
PP	-0.09	0.095	-0.03	0.575	-0.07	0.231	-0.03	0.640
AC	-0.20	**0.001**	-0.13	0.028	-0.13	0.028	-0.10	0.101
PC	-0.17	**0.004**	-0.08	0.156	-0.10	0.103	-0.05	0.388
Vascular factors								
Hypertension	0.09	0.076	0.10	0.065	0.11	0.059	0.09	0.098
Diabetes mellitus	0.07	0.181	0.03	0.575	-0.01	0.868	-0.01	0.854
Dyslipidemia	0.03	0.610	0.02	0.770	0.03	0.603	0.02	0.730
Microbleeds	0.30	**< 0.001**	0.35	**< 0.001**	0.36	**< 0.001**	0.29	**< 0.001**
Lacunae	0.36	**< 0.001**	0.29	**< 0.001**	0.25	**< 0.001**	0.24	**< 0.001**
Multivariable analysis								
BFV	-0.07	0.206	-0.03	0.535	0.02	0.710	0.06	0.348
DAT-AC	-0.15	**0.006**	-0.09	0.091	-0.13	0.033	-0.09	0.122
Hypertension	0.10	**0.033**	0.12	**0.016**	0.13	**0.018**	0.10	0.059
Diabetes mellitus	0.03	0.523	-0.003	0.955	-0.04	0.399	-0.04	0.516
Dyslipidemia	0.01	0.774	0.01	0.904	0.04	0.503	0.02	0.663
Microbleeds	0.27	**< 0.001**	0.33	**< 0.001**	0.35	**< 0.001**	0.27	**< 0.001**
Lacunae	0.30	**< 0.001**	0.23	**< 0.001**	0.19	**< 0.001**	0.19	**< 0.001**

General linear models were used to investigate the effects of BFV, striatal DAT, and vascular
factors on WMHs, after controlling for age, sex, level of education, and intracranial volume. In the
univariable analysis, significant *P*-values are shown in boldface after false discovery rate
correction of 40 regression analyses for multiple comparisons across the 10 predictors and four
outcomes. In the multivariable analysis, significant *P*-values are shown in boldface after false

2 4

discovery rate correction of the four regression analyses for multiple comparisons across the four outcomes. Abbreviations: B, standardized β coefficient; AC, anterior caudate; AP, anterior putamen; BFV, basal forebrain volume; DAT, dopamine transporter; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PC, posterior caudate; PP, posterior putamen; PWMH-A, anterior periventricular white matter hyperintensities; PWMH-P, posterior periventricular white matter hyperintensities.

Table 13. Effect of BFV, striatal DAT uptake, and vascular factors on DLB features after excluding 73 patients who did not satisfy the criteria for probable AD and DLB

	BFV		DAT-AC		PWMH-A	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Univariable analysis						
Cognitive fluctuation	0.97 (0.96~0.99)	**<0.001**	0.66 (0.54~0.80)	**<0.001**	1.00 (1.00~1.00)	0.170
Visual hallucination	0.98 (0.96~0.99)	**0.002**	0.58 (0.45~0.74)	**<0.001**	1.00 (1.00~1.00)	0.878
RBD	1.00 (0.99~1.01)	0.657	0.76 (0.63~0.91)	**0.004**	1.00 (1.00~1.00)	0.630
Multivariable analysis						
Cognitive fluctuation	0.98 (0.97~0.99)	**0.001**	0.72 (0.58~0.89)	**0.002**	1.00 (1.00~1.00)	0.705
Visual hallucination	0.98 (0.97~1.00)	0.044	0.61 (0.47~0.79)	**<0.001**	1.00 (1.00~1.00)	0.282
RBD	1.00 (0.99~1.01)	0.732	0.74 (0.60~0.90)	**0.003**	1.00 (1.00~1.00)	0.313

Data are the results of logistic regression models of DLB clinical features (cognitive fluctuation, visual hallucination, and RBD) using BFV, DAT-AC, and PWMH-A as predictors after controlling for age, sex, level of education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of regression analyses for 9 univariable analyses and 3 multivariable analyses. Abbreviations: BFV, basal forebrain volume; CI, confidence interval; DAT-AC, dopamine transporter uptake in the anterior caudate; DLB, dementia with Lewy bodies; OR, odds ratio; PWMH-A, anterior periventricular white matter hyperintensities; RBD, rapid eye movement sleep behavior disorder.

Table 14. Effect of BFV, striatal DAT uptake, and vascular factors on parkinsonism after excluding 73 patients who did not satisfy the criteria for probable AD and DLB

	BFV		DAT-AC		PWMH-A	
	B	*P*	B	*P*	B	*P*
Univariable analysis						
Total UPDRS motor score	-0.17	**0.008**	-0.24	**< 0.001**	0.11	0.113

	B	P	B	P	B	P
Axial	-0.11	0.072	-0.13	0.036	0.13	0.044
Bradykinesia	-0.19	**0.003**	-0.22	**< 0.001**	0.10	0.132
Rigidity	-0.09	0.170	-0.24	**< 0.001**	0.09	0.192
Tremor	-0.08	0.199	-0.08	0.206	0.03	0.658
Multivariable analysis						
Total UPDRS motor score	-0.11	0.101	-0.20	**0.002**	0.06	0.386
Axial	-0.08	0.238	-0.09	0.162	0.11	0.105
Bradykinesia	-0.13	0.044	-0.18	**0.006**	0.06	0.414
Rigidity	-0.02	0.782	-0.23	**< 0.001**	0.04	0.519
Tremor	-0.06	0.339	-0.06	0.367	0.01	0.861

General linear models were used to investigate the effects of BFV, DAT-AC, and PWMH-A on parkinsonism after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction for multiple comparisons of regression analyses for 15 univariable analyses and 4 multivariable analyses for 4 subscores of the UPDRS motor score. Abbreviations: B, standardized β coefficient; BFV, basal forebrain volume; DAT-AC, dopamine transporter uptake in the anterior caudate; PWMH-A, anterior periventricular white matter hyperintensities; UPDRS, Unified Parkinson's Disease Rating Scale.

Table 15. Effect of BFV and WMHs on striatal DAT uptake after excluding 73 patients who did not satisfy the criteria for probable AD and DLB

	BFV		PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	P	B	P	B	P	B	P	B	P
DAT										
AP	0.19	**< 0.001**	-0.09	0.082	-0.05	0.330	-0.08	0.127	-0.03	0.548
PP	0.13	0.014	-0.06	0.183	-0.01	0.819	-0.06	0.263	-0.01	0.881
AC	0.28	**< 0.001**	-0.16	**0.001**	-0.10	0.052	-0.12	0.034	-0.08	0.181
PC	0.26	**< 0.001**	-0.12	0.023	-0.04	0.469	-0.07	0.246	-0.02	0.796

Univariable general linear models were used to investigate effects of BFV and WMHs on striatal DAT uptake after controlling for age, sex, education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of regressions analyses for 20 tests. Abbreviations: AC, anterior caudate; AP, anterior putamen; BFV, basal forebrain volume; DAT, dopamine transporter uptake; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PC, posterior caudate; PP, posterior putamen; PWMH-A, anterior periventricular WMH; PWMH-P, posterior PWMH.

Table 16. Univariable analysis of the effect of BFV, DAT-AC, and PWMH-A on cognition after excluding 73 patients who did not satisfy the criteria for probable AD and DLB

	BFV		DAT-AC		PWMH-A	
	B	P	B	P	B	P
Digit span Backward	-0.02	0.723	0.10	0.108	-0.19	**0.005**
K BNT	0.24	**< 0.001**	0.19	**0.002**	-0.18	**0.007**
RCFT copy	0.18	**0.003**	0.24	**< 0.001**	-0.11	0.076
SVLT immediate recall	0.28	**< 0.001**	0.25	**< 0.001**	-0.14	**0.028**
SVLT delayed recall	0.26	**< 0.001**	0.17	**0.006**	-0.18	**0.006**
SVLT recognition	0.19	**0.002**	0.12	0.053	-0.10	0.120
RCFT immediate recall	0.28	**< 0.001**	0.19	**0.001**	-0.14	**0.030**
RCFT delayed recall	0.26	**< 0.001**	0.18	**0.001**	-0.12	0.047
RCFT recognition	0.26	**< 0.001**	0.19	**0.002**	-0.15	**0.023**
COWAT animal	0.33	**< 0.001**	0.21	**< 0.001**	-0.26	**< 0.001**
COWAT phonemic	0.16	**0.011**	0.15	**0.014**	-0.12	0.074
Stroop color reading	0.30	**< 0.001**	0.27	**< 0.001**	-0.23	**0.001**

Univariable general linear models were used to investigate effects of BFV, DAT-AC, and PWMH-A on cognition after controlling for age, sex, education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. Abbreviations: BFV, basal forebrain volume; COWAT, controlled oral word association test; DAT-AC, dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston naming test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey−Osterrieth complex figure Test; SVLT, Seoul verbal learning test.

Table 17. Multivariable analysis of the effect of BFV, DAT-AC, and PWMH-A on cognition after excluding 73 patients who did not satisfy the criteria for probable AD and DLB

	BFV		DAT-AC		PWMH-A	
	B	P	B	P	B	P
Digit span backward	-0.07	0.306	0.09	0.176	-0.18	**0.008**
K-BNT	0.20	**0.002**	0.12	0.066	-0.13	0.042
RCFT copy	0.12	0.054	0.20	**0.001**	-0.06	0.343
SVLT immediate recall	0.22	**<0.001**	0.17	**0.005**	-0.08	0.194

SVLT delayed recall	0.23	**<0.001**	0.08	0.177	-0.14	0.037
SVLT recognition	0.17	**0.008**	0.06	0.343	-0.07	0.292
RCFT immediate recall	0.24	**<0.001**	0.10	0.079	-0.08	0.168
RCFT delayed recall	0.22	**<0.001**	0.11	0.055	-0.07	0.232
RCFT recognition	0.22	**<0.001**	0.11	0.087	-0.10	0.124
COWAT animal	0.28	**<0.001**	0.10	0.094	-0.20	**0.002**
COWAT phonemic	0.12	0.065	0.11	0.105	-0.09	0.199
Stroop color reading	0.23	**<0.001**	0.17	**0.006**	-0.17	**0.010**

Multivariable general linear models were used to investigate the effects of BFV, DAT-AC, and PWMH-A on cognition, after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction for multiple comparisons of the regression analyses of 12 tests. Abbreviations: B, standardized β coefficient; BFV, basal forebrain volume; COWAT, Controlled Oral Word Association Test; DAT-AC, dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston Naming Test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey−Osterrieth Complex Figure Test; SVLT, Seoul Verbal Learning Test.

Figures 7-8 and Tables 18-22 present the results of sensitivity analyses conducted separately for the non-AD/non-DLB, AD, DLB, AD/DLB, and combined DLB + AD/DLB subgroups. Overall, the results were consistent with the main findings, with the subgroups containing DLB (either DLB or AD/DLB) appearing to drive the observed effects.

Fig. 7. Voxel-wise analyses for the associations of DAT uptake with BF volume and PWMH-A in the AD, DLB, AD/DLB, and combined DLB+AD/DLB subgroups. Univariable and multivariable analyses for voxel-wise DAT uptake using BF volume and PWMH-A as predictors. There were no significant findings in the non-AD/non-DLB subgroup. All analyses were performed after controlling for age, sex, education, intracranial volume, hypertension, diabetes, dyslipidemia, microbleeds, and lacunes. Negative correlations between WMH and DAT were tested, and positive correlations were tested between BF volume and DAT. Effect sizes (r score) were indicated by color intensities within statistically significant regions identified by multiple comparisons correction (false discovery rate [FDR] corrected, P <0.05). Abbreviations: AC, anterior caudate; BF, basal forebrain; DAT, dopamine transporter uptake; WMHs, white matter hyperintensities; PWMH-A, anterior periventricular WMH.

**Fig. 8**. Voxel-wise analyses for the associations of WMHs with BF volume and DAT-AC in the combined DLB+AD/DLB subgroup. Univariable and multivariable analyses for voxel-wise WMHs using BF volume and DAT-AC as predictors. There were significant findings in the non-AD/non-DLB, AD, DLB, and AD/DLB subgroups. All analyses were performed after controlling for age, sex, education, intracranial volume, hypertension, diabetes, dyslipidemia, microbleeds, and lacunes. Negative correlations between WMHs and predictors were tested. Effect sizes (r score) were indicated by color intensities within statistically significant regions identified by multiple comparisons correction (false discovery rate [FDR] corrected, P <0.05). Abbreviations: AC, anterior caudate; BF, basal forebrain; DAT, dopamine transporter uptake; WMHs, white matter hyperintensities.

Table 18. Effect of BF volume and WMHs on striatal DAT uptake in the non-AD/non-DLB, AD, DLB, and AD/DLB subgroups

	BF volume		PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	P	B	P	B	P	B	P	B	P
Non-AD/non-DLB										
DAT-AP	0.13	0.262	0.13	0.393	0.23	0.128	0.09	0.595	0.18	0.159
DAT-PP	0.08	0.524	0.00	0.995	0.13	0.409	0.09	0.621	0.11	0.417
DAT-AC	0.14	0.217	-0.09	0.550	0.15	0.329	0.03	0.867	0.15	0.218
DAT-PC	0.11	0.352	-0.12	0.439	0.15	0.339	0.04	0.831	0.14	0.268
AD										
DAT-AP	0.15	0.206	-0.09	0.547	-0.25	0.099	-0.15	0.251	-0.19	0.141
DAT-PP	0.23	0.053	-0.07	0.635	-0.15	0.312	-0.12	0.337	-0.14	0.277
DAT-AC	0.26	0.020	-0.11	0.411	-0.21	0.143	-0.15	0.211	-0.15	0.221
DAT-PC	0.28	0.019	0.03	0.827	-0.05	0.730	-0.02	0.865	-0.02	0.844
DLB										
DAT-AP	0.28	**0.004**	-0.14	0.167	-0.01	0.954	-0.15	0.122	-0.07	0.442
DAT-PP	0.28	**0.005**	-0.13	0.207	0.02	0.875	-0.09	0.356	-0.03	0.735
DAT-AC	0.31	**0.001**	-0.20	0.035	-0.05	0.609	-0.20	0.024	-0.13	0.124

	B	P	B	P	B	P	B	P	B	P
DAT-PC	0.29	**0.002**	-0.16	0.080	-0.01	0.898	-0.18	0.045	-0.11	0.187
AD/DLB										
DAT-AP	0.04	0.702	-0.10	0.357	-0.11	0.288	-0.19	0.065	-0.05	0.582
DAT-PP	-0.13	0.195	-0.01	0.957	0.00	0.996	-0.10	0.339	0.01	0.907
DAT-AC	0.13	0.163	-0.25	0.014	-0.23	0.020	-0.20	0.040	-0.16	0.103
DAT-PC	0.15	0.128	-0.24	0.022	-0.16	0.120	-0.18	0.070	-0.08	0.397
DLB+AD/DLB										
DAT-AP	0.17	**0.010**	-0.10	0.139	-0.04	0.594	-0.14	0.033	-0.05	0.406
DAT-PP	0.09	0.213	-0.07	0.301	0.01	0.845	-0.09	0.173	-0.01	0.889
DAT-AC	0.25	**<0.001**	-0.20	**0.003**	-0.10	0.114	-0.17	**0.008**	-0.12	0.059
DAT-PC	0.23	**<0.001**	-0.17	0.011	-0.05	0.475	-0.14	0.026	-0.07	0.271

Univariable general linear models were used to investigate the effects of BF volume and WMHs on striatal DAT uptake after controlling for age, sex, education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunes, and intracranial volume. Significant P-values are shown in boldface after false discovery rate correction for multiple comparisons of regressions analyses for 20 tests in each subgroup. Abbreviations: AC, anterior caudate; AP, anterior putamen; BF, basal forebrain; DAT, dopamine transporter uptake; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PC, posterior caudate; PP, posterior putamen; PWMH-A, anterior periventricular WMH; PWMH-P, posterior PWMH.

Table 19. Effect of BF volume, DAT-AC, and vascular factors on WMHs in the non-AD/non-DLB, AD, DLB, and AD/DLB subgroups and the combined DLB+AD/DLB subgroup

	PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	*P*	B	*P*	B	*P*	B	*P*
Non-AD/non-DLB								
BF volume	-0.10	0.329	0.04	0.697	-0.03	0.727	0.05	0.641
DAT-AC	-0.04	0.700	0.11	0.340	0.03	0.741	0.15	0.265
Hypertension	0.11	0.278	0.02	0.806	0.08	0.377	0.00	0.995
Diabetes mellitus	0.00	0.993	0.05	0.598	-0.03	0.740	0.06	0.577
Dyslipidemia	0.19	0.069	0.19	0.061	0.09	0.357	0.10	0.387
Microbleeds	0.23	0.019	0.20	0.034	0.16	0.065	0.03	0.793
Lacunae	0.52	**<0.001**	0.62	**<0.001**	0.74	**<0.001**	0.63	**<0.001**
AD								
BF volume	-0.08	0.456	-0.01	0.947	-0.05	0.678	0.06	0.658
DAT-AC	-0.07	0.565	-0.16	0.168	-0.14	0.281	-0.17	0.197
Hypertension	0.16	0.162	0.17	0.112	0.15	0.232	0.06	0.663
Diabetes mellitus	0.06	0.590	-0.07	0.499	-0.03	0.790	-0.02	0.835

Dyslipidemia	-0.09	0.422	0.00	0.980	0.00	0.969	0.05	0.710
Microbleeds	0.32	**0.003**	0.38	**<0.001**	0.34	**0.005**	0.33	**0.006**
Lacunae	0.26	**0.017**	0.24	**0.020**	0.21	0.082	0.07	0.557
DLB								
BF volume	-0.03	0.754	-0.09	0.354	0.00	0.983	-0.07	0.458
DAT-AC	-0.16	0.054	-0.02	0.826	-0.19	0.031	-0.12	0.209
Hypertension	0.05	0.475	0.12	0.119	0.12	0.144	0.14	0.102
Diabetes mellitus	0.07	0.358	-0.01	0.877	-0.03	0.677	-0.11	0.187
Dyslipidemia	-0.04	0.597	-0.09	0.278	-0.09	0.247	-0.12	0.156
Microbleeds	0.21	**0.007**	0.23	**0.004**	0.40	**<0.001**	0.23	**0.005**
Lacunae	0.27	**0.001**	0.19	0.029	0.05	0.546	0.15	0.094
AD/DLB								
BF volume	-0.14	0.112	-0.05	0.582	0.03	0.772	0.04	0.676
DAT-AC	-0.21	0.025	-0.22	0.026	-0.20	0.039	-0.17	0.096
Hypertension	0.09	0.291	0.01	0.886	0.01	0.899	0.04	0.671
Diabetes mellitus	0.03	0.724	0.09	0.325	-0.06	0.491	0.05	0.576
Dyslipidemia	0.15	0.077	0.10	0.256	0.20	0.026	0.07	0.461
Microbleeds	0.32	**<0.001**	0.36	**<0.001**	0.38	**<0.001**	0.20	**0.022**
Lacunae	0.28	**0.001**	0.25	**0.005**	0.28	**0.002**	0.35	**<0.001**
DLB+AD/DLB								
BF volume	-0.07	0.242	-0.06	0.339	0.02	0.784	0.00	0.951
DAT-AC	-0.16	**0.008**	-0.08	0.195	-0.18	**0.008**	-0.12	0.070
Hypertension	0.08	0.147	0.09	0.106	0.12	0.050	0.12	0.053
Diabetes mellitus	0.02	0.661	0.02	0.749	-0.06	0.337	-0.04	0.537
Dyslipidemia	0.03	0.596	-0.01	0.847	0.02	0.686	-0.03	0.673
Microbleeds	0.24	**<0.001**	0.28	**<0.001**	0.30	**<0.001**	0.19	**0.002**
Lacunae	0.31	**<0.001**	0.23	**<0.001**	0.20	**0.001**	0.25	**<0.001**

General linear models were used to investigate the effects of BF, striatal DAT, and vascular factors on WMHs after controlling for age, sex, level of education, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction of the four regression analyses for multiple comparisons across the four outcomes. Abbreviations: B, standardized β coefficient; AC, anterior caudate; AP, anterior putamen; BF, basal forebrain; DAT, dopamine transporter; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PC, posterior caudate; PP, posterior putamen; PWMH-A, anterior periventricular white matter hyperintensities; PWMH-P, posterior periventricular white matter hyperintensities.

Table 20. Effect of BF volume, DAT-AC, and anterior PWMHs on DLB features in the non-AD/non-DLB, AD, DLB, and AD/DLB subgroups and the combined DLB+AD/DLB subgroup

	BF volume		DAT-AC		PWMH-A	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
DLB						
Cognitive fluctuation	0.98 (0.96~1.00)	**0.041**	0.95 (0.69~1.32)	0.775	1.00 (1.00~1.00)	0.263
Visual hallucination	0.98 (0.95~1.00)	**0.043**	0.74 (0.53~1.01)	0.066	1.00 (1.00~1.00)	0.951
RBD	1.00 (0.98~1.02)	0.875	0.68 (0.49~0.91)	**0.011**	0.99 (0.99~1.00)	**0.035**
AD/DLB						
Cognitive fluctuation	0.96 (0.92~0.99)	**0.016**	0.69 (0.32~1.36)	0.306	1.00 (1.00~1.00)	0.399
Visual hallucination	0.98 (0.94~1.01)	0.173	0.59 (0.34~0.99)	0.051	1.00 (1.00~1.00)	0.102
RBD	1.02 (1.00~1.04)	0.128	1.21 (0.82~1.81)	0.340	1.00 (1.00~1.00)	0.536
DLB+AD/DLB						
Cognitive fluctuation	0.97 (0.96~0.99)	**0.001**	0.89 (0.68~1.17)	0.412	1.00 (1.00~1.00)	0.773
Visual hallucination	0.98 (0.97~1.00)	0.058	0.68 (0.51~0.88)	**0.004**	1.00 (1.00~1.00)	0.212
RBD	1.01 (0.99~1.02)	0.238	0.83 (0.67~1.03)	0.101	1.00 (1.00~1.00)	0.323

Data are the results of logistic regression models of DLB clinical features (cognitive fluctuation, visual hallucination, and RBD) using BF volume, DAT-AC, and PWMH-A as predictors after controlling for age, sex, level of education, HTN, DM, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Abbreviations: BF, basal forebrain; CI, confidence interval; DAT-AC, dopamine transporter uptake in the anterior caudate; DLB, dementia with Lewy bodies; OR, odds ratio; PWMH-A, anterior periventricular white matter hyperintensities; RBD, rapid eye movement sleep behavior disorder.

Table 21. Effect of BF volume, DAT-AC, and anterior PWMH on parkinsonism in the non-AD/non-DLB, AD, DLB, and AD/DLB subgroups and the combined DLB+AD/DLB subgroup

	BF volume		DAT-AC		PWMH-A	
	B	*P*	B	*P*	B	*P*
Non-AD/non-DLB						
Total UPDRS motor score	0.10	0.431	-0.27	0.068	-0.35	**0.041**
Axial	0.17	0.190	0.02	0.909	-0.15	0.348
Bradykinesia	0.13	0.309	-0.41	**0.007**	-0.33	0.054
Rigidity	-0.08	0.565	-0.16	0.285	-0.45	**0.011**

	B	P	B	P	B	P
Tremor	-0.02	0.877	-0.11	0.504	-0.18	0.325
AD						
Total UPDRS motor score	-0.18	0.217	0.13	0.401	0.07	0.664
Axial	-0.15	0.270	0.07	0.621	0.21	0.191
Bradykinesia	-0.09	0.519	0.06	0.704	0.14	0.420
Rigidity	-0.06	0.664	0.08	0.608	0.11	0.502
Tremor	0.11	0.464	0.11	0.464	-0.18	0.290
DLB						
Total UPDRS motor score	-0.09	0.376	-0.29	**0.005**	-0.11	0.300
Axial	-0.01	0.924	-0.14	0.170	0.02	0.823
Bradykinesia	-0.14	0.185	-0.27	**0.008**	-0.16	0.136
Rigidity	-0.01	0.914	-0.34	**0.001**	-0.09	0.396
Tremor	-0.14	0.173	-0.12	0.225	0.08	0.454
AD/DLB						
Total UPDRS motor score	-0.12	0.253	-0.13	0.211	0.28	**0.016**
Axial	-0.15	0.148	-0.06	0.555	0.16	0.166
Bradykinesia	-0.12	0.259	-0.14	0.184	0.32	**0.005**
Rigidity	-0.01	0.960	-0.14	0.201	0.22	0.070
Tremor	-0.04	0.750	0.00	0.972	0.08	0.525
DLB+AD/DLB						
Total UPDRS motor score	-0.10	0.178	-0.22	**0.003**	0.05	0.496
Axial	-0.05	0.491	-0.08	0.257	0.10	0.181
Bradykinesia	-0.14	0.063	-0.21	**0.005**	0.04	0.605
Rigidity	-0.01	0.893	-0.26	**< 0.001**	0.03	0.685
Tremor	-0.08	0.306	-0.07	0.342	0.05	0.497

General linear models were used to investigate the effects of BF volume, DAT-AC, and PWMH-A on parkinsonism after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction for multiple comparisons of regression analyses for four subscores of the UPDRS motor score. Abbreviations: B, standardized β coefficient; BF, basal forebrain; DAT-AC, dopamine transporter uptake in the anterior caudate;

PWMH-A, anterior periventricular white matter hyperintensities; UPDRS, Unified Parkinson's Disease Rating Scale.

Table 22. Multivariable analysis of the effect of BF volume, DAT-AC, and PWMH-A on cognition in the non-AD/non-DLB, AD, DLB, and AD/DLB subgroups and the combined DLB+AD/DLB subgroup

	BF volume		DAT-AC		PWMH-A	
	B	P	B	P	B	P
Non-AD/non-DLB						
Digit span backward	-0.15	0.317	0.10	0.529	0.04	0.832
K-BNT	0.03	0.860	0.19	0.247	-0.03	0.887
RCFT copy	0.13	0.334	0.21	0.143	0.01	0.973
SVLT immediate recall	0.09	0.503	0.41	**0.006**	-0.04	0.785
SVLT delayed recall	0.07	0.602	0.43	**0.005**	-0.12	0.478
SVLT recognition	0.24	0.094	0.24	0.128	0.03	0.856
RCFT immediate recall	0.02	0.877	0.33	0.036	0.11	0.527
RCFT delayed recall	-0.07	0.591	0.39	0.014	0.01	0.939
RCFT recognition	-0.07	0.639	0.25	0.145	-0.08	0.674
COWAT semantic	0.02	0.874	0.38	0.020	0.00	0.995
COWAT phonemic	0.00	0.985	0.20	0.219	0.01	0.948
Stroop color reading	0.14	0.304	0.10	0.504	-0.12	0.537
AD						
Digit span backward	-0.23	0.110	-0.01	0.929	-0.13	0.423
K-BNT	0.08	0.540	0.11	0.454	-0.40	0.008
RCFT copy	0.11	0.456	-0.07	0.639	-0.05	0.777
SVLT immediate recall	0.06	0.635	0.10	0.462	0.01	0.943
SVLT delayed recall	0.11	0.390	0.11	0.425	-0.04	0.772
SVLT recognition	-0.02	0.846	0.08	0.526	-0.02	0.872
RCFT immediate recall	0.11	0.351	0.03	0.798	0.06	0.659
RCFT delayed recall	0.08	0.498	0.00	0.981	-0.03	0.823
RCFT recognition	0.28	0.030	-0.11	0.397	-0.04	0.753

COWAT semantic	0.35	0.006	0.20	0.137	-0.02	0.871
COWAT phonemic	-0.06	0.668	0.19	0.208	0.12	0.451
Stroop color reading	-0.03	0.795	0.00	0.975	-0.07	0.628
DLB						
Digit span backward	-0.09	0.372	0.03	0.740	-0.24	0.013
K-BNT	0.16	0.110	0.01	0.939	-0.12	0.222
RCFT copy	0.08	0.432	0.19	0.045	0.01	0.908
SVLT immediate recall	0.29	**0.004**	0.08	0.377	-0.05	0.631
SVLT delayed recall	0.25	0.017	0.02	0.809	-0.13	0.214
SVLT recognition	0.14	0.207	-0.02	0.882	-0.04	0.679
RCFT immediate recall	0.29	**0.004**	0.06	0.511	-0.10	0.296
RCFT delayed recall	0.21	0.041	0.11	0.261	-0.06	0.545
RCFT recognition	0.12	0.226	0.12	0.208	-0.11	0.279
COWAT semantic	0.19	0.061	0.07	0.444	-0.22	0.027
COWAT phonemic	0.17	0.107	0.01	0.947	-0.10	0.343
Stroop color reading	0.18	0.082	0.18	0.074	-0.19	0.061
AD/DLB						
Digit span backward	0.00	0.967	0.03	0.792	-0.20	0.083
K-BNT	0.38	**<0.001**	0.20	0.049	-0.01	0.916
RCFT copy	0.21	0.031	0.22	0.029	-0.19	0.068
SVLT immediate recall	0.15	0.122	0.13	0.189	-0.31	**0.005**
SVLT delayed recall	0.19	0.065	0.12	0.265	-0.29	**0.009**
SVLT recognition	0.21	0.047	0.06	0.589	-0.18	0.108
RCFT immediate recall	0.23	**0.015**	0.14	0.164	-0.20	0.058
RCFT delayed recall	0.29	**0.002**	0.18	0.062	-0.15	0.129
RCFT recognition	0.29	**0.006**	0.17	0.112	-0.21	0.058
COWAT semantic	0.34	**0.001**	-0.01	0.935	-0.30	**0.006**
COWAT phonemic	0.21	0.053	0.08	0.491	-0.22	0.068
Stroop color reading	0.40	**<0.001**	0.08	0.469	-0.20	0.072
DLB+AD/DLB						

Digit span backward	-0.03	0.658	0.05	0.489	-0.21	**0.005**
K-BNT	0.23	**0.001**	0.08	0.238	-0.08	0.290
RCFT copy	0.13	0.056	0.21	**0.002**	-0.07	0.331
SVLT immediate recall	0.26	**<0.001**	0.11	0.102	-0.13	0.059
SVLT delayed recall	0.26	**<0.001**	0.05	0.494	-0.18	**0.013**
SVLT recognition	0.21	**0.003**	0.01	0.866	-0.10	0.175
RCFT immediate recall	0.28	**<0.001**	0.09	0.165	-0.13	0.054
RCFT delayed recall	0.26	**<0.001**	0.13	0.058	-0.10	0.161
RCFT recognition	0.20	**0.005**	0.14	0.050	-0.14	0.061
COWAT semantic	0.26	**<0.001**	0.04	0.512	-0.25	**0.001**
COWAT phonemic	0.16	**0.027**	0.05	0.519	-0.16	0.039
Stroop color reading	0.28	**<0.001**	0.14	0.050	-0.19	**0.007**

Multivariable general linear models were used to investigate the effects of BF volume, DAT-AC, and PWMH-A on cognition, after controlling for age, sex, education, hypertension, diabetes mellitus, dyslipidemia, number of microbleeds, number of lacunae, and intracranial volume. Significant *P*-values are shown in boldface after false discovery rate correction for multiple comparisons of the regression analyses of 12 tests. Abbreviations: B, standardized β coefficient; BF, basal forebrain; COWAT, Controlled Oral Word Association Test; DAT-AC, dopamine transporter uptake in the anterior caudate; K-BNT, Korean version of the Boston Naming Test; PWMH-A, anterior periventricular white matter hyperintensities; RCFT, Rey–Osterrieth Complex Figure Test; SVLT, Seoul Verbal Learning Test.

4. DISCUSSION

I evaluated the relationships among striatal DAT uptake, BF volume, WMH burden, and clinical symptoms in patients with cognitive impairment due to AD, DLB, or mixed AD/DLB. The major findings are as follows. First, lower DAT-AC was associated with lower BF volume independent of vascular factors. Second, lower DAT-AC was associated with a higher PWMH-A, but not with DWMHs, independent of the BF volume. Both DWMHs and PWMHs were associated with hypertension and the number of microbleeds and lacunae. Third, both lower BF volume and DAT-AC were independently associated with an increased risk of cognitive fluctuation and visual hallucination, whereas lower DAT-AC was additionally associated with an increased risk of RBD and higher UPDRS motor scores. Fourth, lower BF volume and DAT-AC were independently associated with widespread cognitive dysfunction, whereas higher PWMH-A was associated with attention/executive dysfunction. Taken together, the results suggest that dopaminergic and cholinergic degeneration are closely related and reflect the underlying LB-related degeneration.

PWMH-A may be a manifestation of axonal alterations caused by the interplay between Lewy body-related degeneration and vascular pathology.

Lower striatal DAT uptake, especially in the AC, was associated with a lower BF volume, independent of vascular factors. To the best of my knowledge, no previous studies have evaluated the association between striatal DAT function and cholinergic BF degeneration. This finding is in line with the previous pathological studies showing that LB pathologies are associated with severe degeneration of the cholinergic neurons in the BF.[2-4] Considering presynaptic α-synuclein aggregates cause synaptic dysfunction and subsequent loss of dendritic spines in postsynaptic neurons,[35] destruction of BF cholinergic system might be induced by the spreading of LB-related degeneration or α-synuclein from the substantia nigra[36, 37] or caudate nucleus,[38] whose neurons project directly to BF cholinergic cells. Although both AD and DLB were independently associated with lower BF volume, only DLB was associated with lower DAT-AC independent of AD (Table 11). Therefore, the association between the DAT-AC and BF volume was not confounded by the presence of AD. These results emphasize the critical role of nigrostriatal dysfunction in cholinergic degeneration.

Lower DAT-AC was associated with higher PWMH-A. In line with these results, previous studies have shown significant association between lower striatal DAT uptake and more severe WMHs in patients with Parkinson's disease (PD)[39] and clinically normal elderly.[40] In previous studies, however, although patients with LBD had larger volumes of WMHs than cognitively normal participants,[15, 16] concomitant AD-related[12-14] or vascular related risk factors were regarded as a major contributor to WMHs rather than LBD pathologies itself.[16, 41, 42] However, the association between DAT-AC and PWMH-A in this study did not disappear after controlling for vascular risk factors, BF volume, and even the presence of AD (Table 23).

Table 23. Independent effect of BFV, striatal DAT uptake, and vascular factors on WMHs after adjusting for presences of AD and DLB

Predictors	PWMH-A		PWMH-P		DWMH-A		DWMH-P	
	B	P	B	P	B	P	B	P
Multivariable analysis								
AD	0.002	0.957	0.04	0.359	0.07	0.160	0.08	0.109
DLB	0.01	0.766	-0.01	0.851	-0.05	0.296	-0.08	0.110
BFV	-0.08	0.086	-0.03	0.533	-0.01	0.867	0.04	0.452
DAT-AC	-0.13	**0.008**	-0.07	0.157	-0.12	**0.026**	-0.09	0.129
Hypertension	0.10	**0.021**	0.10	**0.028**	0.11	**0.027**	0.08	0.107
Diabetes mellitus	0.03	0.439	0.02	0.717	-0.04	0.381	-0.02	0.760
Dyslipidemia	0.03	0.469	0.02	0.578	0.04	0.458	0.04	0.469
Microbleeds	0.27	**< 0.001**	0.29	**< 0.001**	0.28	**< 0.001**	0.19	**< 0.001**
Lacunes	0.33	**< 0.001**	0.29	**< 0.001**	0.25	**< 0.001**	0.26	**< 0.001**

General linear models were used to investigate independent effects BFV, DAT-AC and vascular factors on WMHs after controlling for the presences of AD and DLB, age, sex, levels of education and intracranial volume. Abbreviations: AD, Alzheimer's disease; B, standardized beta coefficient; BFV, basal forebrain volume; DAT-AC; dopamine transporter uptake in the anterior caudate; DLB, dementia with Lewy bodies; hyperintensities; DWMH-A, anterior deep white matter hyperintensities; DWMH-P, posterior DWMH; PWMH-A, anterior periventricular WMH; PWMH-P, posterior PWMH.

As DWMHs were not associated with DAT-AC, but both DWMHs and PWMHs were correlated with the presence of hypertension and the number of microbleeds and lacunae, these findings could be interpreted as PWMH-A being an interplay between LBD and SVCI, while DWMH may be primarily related to SVCI.[43, 44] Utilization of DAT imaging, quantitative measurement of DAT uptake and WMH volume, and simultaneous consideration of AD, LBD, and mixed disease could produce different results.

Several mechanisms may explain the association between the DAT-AC and PWMH-A. First, glymphatic clearance function, which is affected by degenerative diseases, including AD[45] and PD,[46] could be manifested by axonal alterations in the periventricular region. Therefore, the detrimental effects of α-synuclein or LB-related pathologies on axonal integrity,[47] glymphatic dysfunction, or blood-brain barrier disruption[48-50] can be manifested by PWMH-A. Second, the compromise of the neurovascular unit caused by the degeneration of the BF cholinergic system,[51] could induce microvascular abnormalities reflected by PWMH-A and confound its association with DAT-AC. However, the association between the DAT-AC and PWMH-A remained significant after controlling for BF volume (Table 5). Moreover, although the association between BF volume and PWMH-A disappeared after controlling for DAT-AC, a lower BF volume tended to be associated with a higher PWMH-A. These results may provide evidence that degenerative processes involving the cholinergic and dopaminergic systems are important for white matter integrity or axonal degeneration reflected by PWMH-A.[45-50, 52]

Lower BF volume and DAT-AC were independently associated with an increased risk of cognitive fluctuation and visual hallucinations, while only lower DAT-AC was associated with an increased risk of RBD and higher UPDRS total motor scores and bradykinesia and rigidity subscores. These results are consistent with previous studies showing that cholinergic and dopaminergic system have been implicated in the core symptoms of LBD including cognitive fluctuation[53, 54] and visual hallucination.[54, 55] However, this study is the first to evaluate the independent effects of the two predictors on core symptoms of LBD, and the independent contribution of cholinergic degeneration raises the possibility that patients with severe BF atrophy could exhibit visual hallucination or cognitive fluctuation without significant dopaminergic degeneration, which represents a brain-first rather than body-first subtype[56] among multiple distinct subtypes of LBD.[57] Further studies assessing the cholinergic system and subtypes of LBD are needed to address these issues.

Lower BF volume and DAT-AC were independently associated with widespread cognitive impairment, and higher PWMH-A was associated with attention/executive dysfunction. Only a few studies have evaluated the independent effects of cholinergic and dopaminergic degeneration on cognitive dysfunction.[58, 59] In studies performed in patients with PD, dopaminergic and cholinergic degeneration were independently associated with attentional, executive, and memory dysfunction, but not visuospatial dysfunction. In addition, the interaction effects were significant in both attention and executive domains. However, in this study, BF volume and DAT-AC affected all cognitive domains and had synergistic interaction effects on visuospatial and language dysfunction. The study participants further included patients with AD and mixed disease, and the different methodologies used to measure cholinergic and dopaminergic degeneration may have led to different results in this study. Meanwhile, the effects of DWMHs on cognitive dysfunction were not significant after controlling for DAT-AC and BF volume (data not shown). Considering that PWMHs could reflect axonal degeneration caused by degenerative disease,[52] the significant interaction effect of PWMH-A and BF volume on attention in this study may support the compensatory role of cholinergic neurons in maintaining attention observed in previous studies.[60, 61]

I also performed subgroup analyses to explore disease-specific effects. Sensitivity analyses (Figures 6-7 and Supplementary Tables 18-22) showed that lower BF volume was associated with reduced DAT-AC in the DLB and combined DLB + AD/DLB subgroups. Additionally, a significant negative association between DAT-AC and anterior PWMHs was observed in the combined DLB + AD/DLB subgroup. Lower DAT-AC and BF volume were significantly associated with cognitive fluctuations and visual hallucinations in the DLB and AD/DLB subgroups, and lower DAT-AC was linked to parkinsonism in the DLB and combined DLB + AD/DLB subgroups. In contrast, these associations were less significant in the AD subgroup, possibly due to the small sample size. Since LB-related neurodegeneration cannot be completely ruled out based solely on clinical symptoms, and given the overlap between AD and DLB pathologies,[62] analyzing them separately could introduce selection bias. The sensitivity analyses, performed on each subgroup separately, yielded similar patterns, further validating the conclusions. Together, these findings highlight the significant role of dopaminergic degeneration in BF neurodegeneration and its relationship with clinical outcomes, including WMHs.

An important clinical implication of the findings is that WMHs, particularly anterior PWMHs, previously regarded mainly as markers of vascular etiology, were closely associated with reduced dopamine transporter uptake, visual hallucinations, and cognitive fluctuations characteristic of LBD. In clinical practice, MRI is routinely utilized as a primary screening tool for dementia assessment, whereas dopamine transporter PET imaging is generally limited to cases with clear parkinsonian features. Therefore, clinicians encountering prominent anterior PWMHs on MRI should consider not only vascular pathology but also the potential presence of LBD. This approach may facilitate earlier detection, diagnosis, and targeted treatment strategies for LBD, contributing to addressing current unmet clinical needs in dementia care. In addition, recent evidence highlights that mixed pathology of AD and LB pathologies is common. For instance, in

the Alzheimer's Disease Neuroimaging Initiative cohort, over 30% of the amyloid-confirmed AD individuals were positive for LB pathology when assessed with CSF α-synuclein seeding amplification assays. Considering this frequent coexistence of AD and LB pathologies, I intentionally included combined AD+DLB cases in the main analysis to better reflect real-world clinical populations.

This study has several limitations. First, among 191 AD diagnoses (76 AD + 115 mixed AD/DLB), 49 individuals (25.7%) were confirmed by FBB PET, while the remaining individuals were not. Although the presence of AD was not associated with DAT-AC or PMWH-A in the subgroup that underwent both FBB and DAT PET scans (Table 11), future studies are needed to investigate the effect of AD pathologies, including amyloid β or tau burden, on the dopaminergic system and WMHs. Second, I did not exclude 73 subjects who did not satisfy the criteria for probable AD or DLB. It was because I aimed to simultaneously evaluate the effects of AD, LBD, and vascular disease on brain changes and cognitive dysfunction. Moreover, even after excluding these subjects, the effects of AD and DLB on BF volume and DAT-AC remained significant (Table 11), demonstrating the robustness of the results. Third, this study included participants who visited dementia clinic with subjective or objective cognitive complaints but not normal controls. The results, therefore, should be interpreted accordingly. Future studies including normal controls are warranted to investigate the effect of each disease markers on brain changes and clinical manifestations encompassing the transition from healthy aging to neurodegenerative disease. Fourth, due to the cross-sectional nature of the study, I cannot establish causality among DAT depletion, cholinergic degeneration, and WMHs. Future longitudinal research is warranted to determine the temporal and causal relationships.

V. CONCLUSION

The results suggest the importance of dopaminergic and cholinergic degeneration as LB-related changes in clinical manifestations. Among the WMHs, PWMH-A may be a manifestation of axonal alterations associated with the interplay between LB-related degeneration and vascular pathologies.

References

1. Brunnstrom H, Gustafson L, Passant U, Englund E. Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr 2009;49:146-149.

2. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983;59:277-289.

3. Lippa CF, Smith TW, Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm (Vienna) 1999;106:525-535.

4. Teipel SJ, Fritz HC, Grothe MJ, Alzheimer's Disease Neuroimaging I. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. Neurology 2020;95:e1301-e1311.

5. Mesulam M. Cholinergic aspects of aging and Alzheimer's disease. Biol Psychiatry 2012;71:760-761.

6. Yoo HS, Jeon S, Cavedo E, et al. Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. Neurology 2022;98:e947-e957.

7. Kang S, Jeon S, Lee Y-g, Ye BS. Striatal dopamine transporter uptake, parkinsonism and cognition in Alzheimer's disease. European Journal of Neurology 2023;30:3105-3113.

8. Kang SW, Jeon S, Lee Y-g, et al. Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. Scientific Reports 2021;11:14394.

9. Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study. Alzheimer's Res Ther 2014;6:52.

10. Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol 2011;7:229-236.

11. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000;15:911-916.

12. Yoshita M, Fletcher E, Harvey D, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006;67:2192-2198.

13. Phuah CL, Chen Y, Strain JF, et al. Association of Data-Driven White Matter Hyperintensity Spatial Signatures With Distinct Cerebral Small Vessel Disease Etiologies. Neurology 2022;99:e2535-e2547.

14. McAleese KE, Walker L, Graham S, et al. Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol 2017;134:459-473.

15. Piccini P, Pavese N, Canapicchi R, et al. White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch Neurol 1995;52:191-194.

16.   Sarro L, Tosakulwong N, Schwarz CG, et al. An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Dement 2017;13:257-266.

17.   Garnier-Crussard A, Cotton F, Krolak-Salmon P, Chételat G. White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution. Alzheimer's Dement 2023;19:3738-3748.

18.   Joki H, Higashiyama Y, Nakae Y, et al. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease. J Neurol Sci 2018;385:99-104.

19.   Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies. Eur J Neurol 2013;20:231-235.

20.   Sarro L, Tosakulwong N, Schwarz CG, et al. An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Dement 2017;13:257-266.

21.   Jeong SH, Lee HS, Jung JH, et al. White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease. Mov Disord 2021;36:1411-1419.

22.   Park M, Baik K, Lee Y-g, et al. Implication of Small Vessel Disease MRI Markers in Alzheimer's Disease and Lewy Body Disease1. J Alzheimer's Dis 2021;83:545-556.

23.   Jung JH, Jeon S, Baik K, et al. Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. Neurobiol Aging 2021;106:45-54.

24.   McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.

25.   Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.

26.   McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.

27.   McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020;94:743-755.

28.   Kang Y, Na D. Seoul Neuropsychological Screening Battery (SNSB): Human Brain Research & Consulting Co. Incheon, 2003.

29.   Fonov V, Coupé P, Eskildsen S, F., Collins L, D. Atrophy specific MRI brain template for Alzheimer's disease and Mild Cognitive Impairment.   Alzheimer's Association International Conference; 2011 2011-07-16; Francehttps://hal.archives-ouvertes.fr/hal-00645521/document https://hal.archives-ouvertes.fr/hal-00645521/file/Fonov_ICAD2012.pdf: S58.

30.   Park G, Hong J, Duffy BA, Lee JM, Kim H. White matter hyperintensities segmentation using the ensemble U-Net with multi-scale highlighting foregrounds. Neuroimage 2021;237:118140.

31.   Douaud G, Smith S, Jenkinson M, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain 2007;130:2375-2386.

32.   Jeon S, Yoon U, Park JS, et al. Fully Automated Pipeline for Quantification and Localization of White Matter Hyperintensity in Brain Magnetic Resonance Image. International Journal of Imaging Systems and Technology 2011;21:193-200.

33.   Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 2008;42:1127-1141.

34.   Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage 2011;56:907-922.

35.   Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-1410.

36.   Gaykema RP, Zaborszky L. Direct catecholaminergic-cholinergic interactions in the basal forebrain. II. Substantia nigra-ventral tegmental area projections to cholinergic neurons. J Comp Neurol 1996;374:555-577.

37.   Jones BE, Cuello AC. Afferents to the basal forebrain cholinergic cell area from pontomesencephalic--catecholamine, serotonin, and acetylcholine--neurons. Neuroscience 1989;31:37-61.

38.   Gielow MR, Zaborszky L. The Input-Output Relationship of the Cholinergic Basal Forebrain. Cell Rep 2017;18:1817-1830.

39.   Jeong SH, Lee HS, Jung JH, et al. White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease. Mov Disord 2021;36:1411-1419.

40.   Rieckmann A, Hedden T, Younger AP, Sperling RA, Johnson KA, Buckner RL. Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. Hum Brain Mapp 2016;37:621-631.

41.   Compta Y, Buongiorno M, Bargallo N, et al. White matter hyperintensities, cerebrospinal amyloid-beta and dementia in Parkinson's disease. J Neurol Sci 2016;367:284-290.

42.   Joki H, Higashiyama Y, Nakae Y, et al. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease. J Neurol Sci 2018;385:99-104.

43.   Ballard C, O'Brien J, Barber B, et al. Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. Ann N Y Acad Sci 2000;903:442-445.

44.   Kenny RA, Shaw FE, O'Brien JT, Scheltens PH, Kalaria R, Ballard C. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J Neurol Neurosurg Psychiatry 2004;75:966-971.

45.   Hsu JL, Wei YC, Toh CH, et al. Magnetic Resonance Images Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction in Alzheimer Disease. Ann Neurol 2023;93:164-174.

46.   He P, Shi L, Li Y, et al. The Association of the Glymphatic Function with Parkinson's Disease Symptoms: Neuroimaging Evidence from Longitudinal and Cross-Sectional Studies. Ann Neurol 2023;94:672-683.

47.   Kurowska Z, Kordower JH, Stoessl AJ, et al. Is Axonal Degeneration a Key Early Event in Parkinson's Disease? J Parkinsons Dis 2016;6:703-707.

48.   Elabi O, Gaceb A, Carlsson R, et al. Human alpha-synuclein overexpression in a mouse model of Parkinson's disease leads to vascular pathology, blood brain barrier leakage and pericyte activation. Sci Rep 2021;11:1120.

49.   Wang Q, Zheng J, Pettersson S, Reynolds R, Tan EK. The link between neuroinflammation and the neurovascular unit in synucleinopathies. Sci Adv 2023;9:eabq1141.

50.   Hourfar H, Aliakbari F, Aqdam SR, et al. The impact of alpha-synuclein aggregates on blood-brain barrier integrity in the presence of neurovascular unit cells. Int J Biol Macromol 2023;229:305-320.

51.   Nizari S, Wells JA, Carare RO, Romero IA, Hawkes CA. Loss of cholinergic innervation differentially affects eNOS-mediated blood flow, drainage of Abeta and cerebral amyloid angiopathy in the cortex and hippocampus of adult mice. Acta Neuropathol Commun 2021;9:12.

52.   McAleese KE, Miah M, Graham S, et al. Frontal white matter lesions in Alzheimer's disease are associated with both small vessel disease and AD-associated cortical pathology. Acta Neuropathologica 2021;142:937-950.

53.   Colloby SJ, Elder GJ, Rabee R, O'Brien JT, Taylor JP. Structural grey matter changes in the substantia innominata in Alzheimer's disease and dementia with Lewy bodies: a DARTEL-VBM study. Int J Geriatr Psychiatry 2017;32:615-623.

54.   Lee YG, Jeon S, Kang SW, Ye BS. Effects of amyloid beta and dopaminergic depletion on perfusion and clinical symptoms. Alzheimers Dement 2023;19:5719-5729.

55.   Perry EK, Kerwin J, Perry RH, Irving D, Blessed G, Fairbairn A. Cerebral Cholinergic Activity Is Related to the Incidence of Visual Hallucinations in Senile Dementia of Lewy Body Type. Dementia and Geriatric Cognitive Disorders 1990;1:2-4.

56.   Borghammer P. The alpha-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. J Parkinsons Dis 2021;11:455-474.

57.   Mastenbroek SE, Vogel JW, Collij LE, et al. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type alpha-synuclein pathology. bioRxiv 2023.

58.   Bohnen NI, Albin RL, Muller ML, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol 2015;72:194-200.

59.   Kim K, Bohnen NI, Muller M, Lustig C. Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease. Neuroimage 2019;190:94-106.

60.   Lapchak PA, Jenden DJ, Hefti F. Compensatory elevation of acetylcholine synthesis in vivo by cholinergic neurons surviving partial lesions of the septohippocampal pathway. J Neurosci 1991;11:2821-2828.

61.   Ishunina TA, Kamphorst W, Swaab DF. Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia. J Neuropathol Exp Neurol 2004;63:1243-1254.

62.   Tosun D, Hausle Z, Iwaki H, et al. A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimer's Dement 2024;20:5114-5131.

Abstract in Korean

루이소체 관련 신경퇴행에서 백질 고신호 병변과 콜린성 결손: 영상 기반 연구

기저 전뇌의 콜린성 신경세포 퇴행과 백질 고신호는 알츠하이머 병과 루이소체 치매에서 신경퇴행에 중요한 역할을 하지만, 이들이 도파민 신경세포 퇴행 및 임상 증상과 어떠한 관계를 가지는지는 아직 명확하지 않다. 본 연구에서는 알츠하이머 병, 루이소체 병 또는 두 질환이 함께 동반된 경우에 해당하는 인지장애 환자 407명을 대상으로 분석을 진행하였다. 모든 참가자는 뇌자기공명영상, 도파민 운반체 양전자 방출 단층촬영, 신경심리검사 및 파킨슨 증상, 인지 변동, 환시, 렘수면 행동장애 평가를 시행하였다. 일반 선형 모델 및 로지스틱 회귀 분석을 이용하여 기저 전뇌의 부피, 전측 미상핵의 도파민 운반체 섭취량, 전측·후측·뇌실주변·심부 영역의 백질 고신호 부피와 임상 증상 간의 관계를 분석하였다. 그 결과, 전측 미상핵의 도파민 운반체 섭취량은 기저 전뇌 부피와 양의 상관관계를 보였으며, 전측 뇌실주변의 백질 고신호 부피와는 음의 상관관계를 나타냈으나, 심부 백질 고신호와는 유의한 관계를 보이지 않았다. 또한, 심부 및 뇌실주변의 백질 고신호 부피는 고혈압, 미세출혈 및 열공경색의 개수와 관련이 있었다. 기저 전뇌 부피 감소와 도파민 운반체 섭취량 감소는 독립적으로 인지 변동 및 환시 위험 증가와 관련이 있었으며, 도파민 운반체 섭취량 감소는 추가적으로 렘수면 행동장애 위험 증가 및 파킨슨 증상의 심화와도 연관이 있었다. 또한, 기저 전뇌 부피 감소와 도파민 운반체 섭취량 감소는 전반적인 인지기능 저하와 연관된 반면, 전측 뇌실주변의 백질 고신호 부피 증가는 집행기능 저하와 관련이 있었다. 결론적으로, 기저 전뇌의 콜린성 신경세포 퇴행과 전측 뇌실주변의 백질 고신호는 도파민 신경세포 퇴행과 밀접한 연관이 있으며, 전측 뇌실주변의 백질 고신호는 루이소체 관련 신경세포 퇴행과 혈관 병리 간의 상호작용으로 인한 축삭 변성을 반영할 가능성이 있다.

_____

핵심되는 말: 알츠하이머 병, 루이소체 병, 백질 고신호, 콜린성 시스템, 도파민 운반체